Companion diagnosis of HTRA1 RNA antagonists
By measuring the HTRA1 level in the aqueous humor or vitreous fluid of patients and utilizing the correlation between HTRA1 mRNA antagonist protein levels before and after treatment, the problem of lacking effective biomarkers in existing technologies has been solved, enabling precise assessment of treatment and determination of dosage regimens for patients with macular degeneration.
Patent Information
- Application Number
- CN202410553084.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-30
- Filing Date
- 2018-12-19
- Publication Date
- 2024-11-19
AI Technical Summary
Current technologies have not been able to effectively utilize HTRA1 mRNA antagonists in the treatment of ocular diseases such as macular degeneration, and there is a lack of effective biomarkers to assess patient response to treatment.
By measuring HTRA1 levels in the aqueous humor or vitreous humor of patients, and utilizing the correlation between HTRA1 mRNA antagonist treatment and HTRA1 protein levels before and after treatment, we can use this information as a biomarker for diagnosis and prognosis, and assess the appropriateness of treatment and the required dosage for each patient.
This provides a method for determining the suitability and dosage regimen of HTRA1 mRNA antagonist therapy for patients, improving the precision and effectiveness of treatment.
Smart Images

Figure BSA0000297937360000191 
Figure BSA0000297937360000211 
Figure BSA0000297937360000321
Abstract
Description
[0001] This application is a divisional application of an application with an international application date of December 19, 2018, international application number PCT / EP2018 / 085721, which entered the Chinese national phase on June 19, 2020, application number 201880082677.0, and invention name “Companion Diagnosis for HTRA1 RNA Antagonists”. Field of the Invention
[0002] The present invention relates to the use of HTRA1 mRNA antagonists in treating ocular disorders such as macular degeneration, and the use of HTRA1 levels in aqueous and vitreous humor as diagnostic biomarkers for the suitability of a subject for treatment with an HTRA1 mRNA antagonist. Background Art
[0003] Serine proteases of the human high temperature requirement A (HTRA) family are ubiquitously expressed PDZ proteases that participate in maintaining protein homeostasis in the extracellular compartment by combining the dual functions of proteases and molecular chaperones. HTRA proteases are involved in the organization of the extracellular matrix, cell proliferation and aging. Modulation of HTRA activity has been implicated in serious diseases, including Duchenne muscular dystrophy (Bakay et al. 2002, Neuromuscul. Disord. 12: 125-141), arthritis such as osteoarthritis (Grau et al. 2006, JBC 281: 6124-6129), cancer, familial ischemic cerebral small vessel disease and age-related macular degeneration, as well as Parkinson's disease and Alzheimer's disease. Human HTRA1 contains an insulin-like growth factor (IGF) binding domain. It has been proposed to regulate IGF availability and cell growth (Zumbrunn and Trueb, 1996, FEES Letters 398: 189-192) and exhibit tumor suppressor properties. HTRA1 expression is downregulated in metastatic melanoma and may therefore indicate the extent of melanoma progression. Overexpression of HTRA1 in metastatic melanoma cell lines reduced proliferation and invasion in vitro and reduced tumor growth in a xenograft mouse model (Baldi et al., 2002, Oncogene 21: 6684-6688). In ovarian cancer, HTRA1 expression is also downregulated. In ovarian cancer cell lines, HTRA1 overexpression induces cell death, while antisense HTRA1 expression promotes anchorage-independent growth (Chien et al., 2004, Oncogene 23: 1636-1644).
[0004] In addition to its effects on the IGF pathway, HTRA1 also inhibits signaling of TGFβ family growth factors (Oka et al., 2004, Development 131: 1041-1053). HTRA1 is able to cleave amyloid precursor protein (APP), and HTRA1 inhibitors cause accumulation of Aβ peptides in cultured cells. Therefore, HTRA1 is also associated with Alzheimer's disease (Grau et al., 2005, Proc. Nat. Acad. Sci. USA. 102: 6021-6026).
[0005] Furthermore, upregulation of HTRA1 has been observed and appears to be associated with Duchenne muscular dystrophy (Bakay et al. 2002, Neuromuscul. Disord. 12: 125-141) and osteoarthritis (Grau et al. 2006, JBC 281: 6124-6129) and AMD (Fritsche, et al. Nat Gen 2013 45(4): 433-9).
[0006] A single nucleotide polymorphism (SNP) in the HTRA1 promoter region (rs11200638) is associated with a 10-fold increased risk of developing age-related macular degeneration (AMD). In addition, the HTRA1 SNP is in linkage disequilibrium with the ARMS2 SNP (rs10490924) associated with an increased risk of developing age-related macular degeneration (AMD). The risk allele is associated with a 2-3 fold increase in HTRA1 mRNA and protein expression, and HTRA is present in drusen in AMD patients (Dewan et al., 2006, Science 314: 989-992; Yang et al., 2006, Science 314: 992-993). Overexpression of HtrA1 induces an AMD-like phenotype in mice. hHTRA transgenic mice (Veierkottn, PlosOne 2011) revealed degradation of the elastic layer of Bruch's membrane, determining choroidal vascular abnormalities (Jones, PNAS, 2011), and increased polypoidal choroidal vasculopathy (PCV) lesions (Kumar, IOVS 2014). In addition, damage to Bruch's membrane has been reported in hHTRA1 Tg mice, which determines a 3-fold increase in CNV after exposure to cigarette smoke (Nakayama, IOVS 2014).
[0007] Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people over 65 years old. With the onset of AMD, the light-sensitive photoreceptor cells at the back of the eye, the underlying pigment epithelium that metabolically supports them, and the clear central vision they provide are gradually lost. Age is the main risk factor for the development of AMD: the likelihood of developing AMD increases threefold after the age of 55. Smoking, light iris color, gender (women are at greater risk), obesity, and repeated exposure to UV radiation also increase the risk of developing AMD. AMD progression can be divided into three stages: 1) early AMD, 2) intermediate AMD, and 3) late AMD. There are two forms of late AMD: dry AMD (also known as geographic atrophy, GA) and wet AMD (also known as exudative AMD). Dry AMD is characterized by the loss of photoreceptors and retinal pigment epithelial cells, which leads to vision loss. Wet AMD is associated with pathological choroidal (also known as subretinal) neovascularization. The leakage of abnormal blood vessels formed during this process can damage the macula and impair vision, ultimately leading to blindness. In some cases, patients can show pathology associated with both types of late AMD. Treatment strategies for wet AMD require frequent injections into the eye and are primarily focused on delaying progression of the disease. There are currently no approved treatments for dry AMD.
[0008] WO2017 / 075212 generally relates to anti-HtrA1 antibodies and methods of use thereof, including using anti-HtrA1 antibodies as biomarkers for selecting patients.
[0009] Tosi et al., IOVS 20017, p162-167, reported that HTRA1 concentrations were elevated in the aqueous humor of patients with neovascular age-related macular degeneration and that treatment with ranibizumab and an antibody targeting VEGF-A normalized the levels of HTRA1 in the aqueous humor.
[0010] WO 2008 / 013893 claims a composition for treating a subject with age-related macular degeneration, the composition comprising a nucleic acid molecule containing an antisense sequence that hybridizes to the HTRA1 gene or mRNA: no antisense molecules are disclosed. WO 2009 / 006460 provides siRNA targeting HTRA1 and its use in treating AMD.
[0011] PCT / EP2017 / 065937 and EP17173964.2, both of which are incorporated by reference in their entirety, disclose antisense oligonucleotides that are potent in vivo inhibitors of HTRA1 mRNA, and therapeutic uses thereof, including for the treatment of macular degeneration. SUMMARY OF THE INVENTION
[0013] The inventors have determined that there is a direct correlation between the suppression of HTRA1 mRNA in retinal epithelial cells from subjects treated with HTRA1 mRNA antagonists and the levels of HTRA1 protein in the subjects' aqueous and vitreous humors. The direct correlation allows for the use of HTRA1 as a biomarker for diagnosis or prognosis to determine the suitability of a subject for treatment with HTRA1 mRNA antagonists, as well as companion diagnostics for treatment with HTRA1 mRNA antagonists, for example in patient monitoring.
[0014] The present invention provides a method for determining the suitability of a subject for treatment with an HTRA1 mRNA antagonist, the method comprising the steps of:
[0015] i) determining the level of HTRA1 in a sample of aqueous humor or vitreous humor obtained from the subject
[0016] ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values;
[0017] to determine whether the subject may be or is suitable for treatment with an HTRA1 mRNA antagonist,
[0018] wherein the subject suffers from or is at risk of developing an ocular disorder such as macular degeneration.
[0019] The present invention provides a diagnostic and prognostic method for determining the suitability of a subject for treatment with an HTRA1 mRNA antagonist, the method comprising the steps of:
[0020] i) determining the level of HTRA1 in a sample of aqueous humor or vitreous humor obtained from the subject
[0021] ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values;
[0022] to determine whether the subject is likely or suitable for treatment with an HTRA1 mRNA antagonist,
[0023] wherein the subject suffers from or is at risk of developing an ocular disorder such as macular degeneration.
[0024] The present invention provides a method for determining a suitable dosage regimen of an HTRA1 mRNA antagonist for a subject in need of treatment with the HTRA1 mRNA antagonist, the method comprising the steps of:
[0025] i) determining the level of HTRA1 in a sample of aqueous humor or vitreous humor obtained from the subject
[0026] ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values;
[0027] to determine whether the subject is likely or suitable for treatment with an HTRA1 mRNA antagonist,
[0028] wherein the subject suffers from or is at risk of developing an ocular disorder such as macular degeneration.
[0029] Advantageously, the sample obtained from the subject referred to in the method or use of the present invention is a sample of the subject's aqueous humor.
[0030] The present invention provides a method of treating a subject in need of treatment with an HTRA1 mRNA antagonist, such as a subject suffering from or at risk of developing macular degeneration, the method comprising:
[0031] i) determining the level of HTRA1 in an aqueous humor or vitreous humor sample obtained from the subject
[0032] ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values;
[0033] iii) to determine whether the subject is likely or suitable for treatment with an HTRA1 mRNA antagonist,
[0034] iv) administering to said subject an effective amount of an HTRA1 mRNA antagonist.
[0035] The present invention provides the use of HTRA1 antibodies as companion diagnostics for HTRA1 RNA antagonist therapy.
[0036] The present invention provides the use of an HTRA1 antibody for detecting HTRA1 levels in an aqueous humor or vitreous humor sample obtained from a subject who is undergoing treatment with an HTRA1 mRNA antagonist, or is being evaluated for suitability for treatment with an HTRA1 mRNA antagonist.
[0037] The invention provides for the use of a biomarker in determining a subject's likely response to a therapeutic comprising an HTRA1 mRNA antagonist, wherein the biomarker comprises an elevated level of HTRA1 in a biological sample obtained from the subject's aqueous humor or vitreous humor compared to the level of HTRA1 obtained from a reference sample of a healthy subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 : Exemplary LNA antisense oligonucleotide antagonist of HTRA1 (SEQ ID NO 13, Compound ID #13, 1)
[0040] Figure 2 : Exemplary LNA antisense oligonucleotide antagonist of HTRA1 (SEQ ID NO 15, compound ID #15, 3)
[0041] Figure 3 : Exemplary LNA antisense oligonucleotide antagonist of HTRA1 (SEQ ID 17, compound ID #17)
[0042] Figure 4 : Exemplary LNA antisense oligonucleotide antagonist of HTRA1 (SEQ ID NO 18, Compound ID #18)
[0043] Figure 5 : Exemplary LNA antisense oligonucleotide antagonist of HTRA1 (SEQ ID NO 19, compound ID #19)
[0044] Figure 6: Usage Figure 2 Non-human primate (NHP) PK / PD study of the indicated compound (Compound ID #15, 3) - See Example 1, IVT administration, 25 μg / eye. A) HTRA1 mRNA levels measured in the retina by qPCR. B) HTRA1 mRNA levels illustrated by ISH. CD) HTRA1 protein levels in the retina and vitreous were quantified by IP-MS, respectively. Points show data for individual animals. Error bars show standard deviation of technical replicates (n=3).
[0045] Figure 7. Use Figure 3 NHP PK / PD studies of compounds shown in (Compound ID#73, 1), 4 (Compound ID#86) and 5 (Compound ID#67) (Example 2): IVT administration, 25 μg / eye. A) HTRA1 mRNA levels measured in the retina by qPCR. B) Oligonucleotide content in the retina measured by oligonucleotide ELISA. C) HTRA1 mRNA levels illustrated by ISH. DE) HTRA1 protein levels in the retina and vitreous were quantified by IP-MS, respectively. Points show data for individual animals. Error bars show standard errors of technical replicates (n=3). FG) Reduction of HTRA1 protein levels in the retina and vitreous, respectively, illustrated by western blot.
[0046] Figure 8. HTRA1 protein quantification - immunocapture and LC-MS method. 8A Schematic diagram of the method, 8B Quantification of HTRA1 protein levels in the retina, vitreous and aqueous humor by LC-MS after administration of LNA antisense compounds targeting HTRA1 mRNA. 8HTRA1 protein is reduced in the retina, vitreous and aqueous humor. 8D. PD analysis in a series of aqueous humor samples collected 2, 7, 14 and 21 days after a single dose of IVT 25μg.
[0047] Fig. 9A Compounds #15, 3 and #17 were administered intravitreally in cynomolgus monkeys and aqueous humor samples were collected on days 3, 8, 15 and 22 post-injection. Proteins from undiluted samples were analyzed by capillary electrophoresis using a Peggy Sue apparatus (Protein Simple). HTRA1 was detected using a custom polyclonal rabbit antiserum. Data from animals #J60154 (vehicle), J60158 (C.Id #15, 3), J60162 (C.Id #17) are presented.
[0048] Fig. 9B Signal intensity was quantified by comparison with purified recombinant (S328A mutant) HTRA1 protein (Origene, #TP700208). Calibration curve is shown here.
[0049] Fig. 9C Upper panel: Calculated HTRA1 aqueous humor concentrations from individual animals plotted against time after injection. Lower panel: Mean HTRA1 concentrations for the vehicle group at each time point were determined and the corresponding relative concentrations for treated animals were calculated. Open circles: individual values, filled circles: group mean. % HTRA1 reduction at day 22 is indicated.
[0050] Fig.10 HTRA1 mRNA is plotted against HTRA1 protein levels in the aqueous humor (blue diamonds) or retina (red squares) of cynomolgus monkeys treated with various LNA molecules targeting the HTRA1 transcript. Values are expressed as percentages normalized to PBS controls.
[0051] Fig.11 Correlation of HTRA1 protein in aqueous humor with (A) HTRA1 protein in the retina and (B) HTRA1 mRNA in the retina in cynomolgus monkeys treated with various LNA molecules targeting the HTRA1 transcript. Values are expressed as percentages normalized to PBS controls.
[0052] Fig. 12A. Mean HTRA1 protein levels on day 36 after IVT LNA application.
[0053] Percentage of HTRA1 inhibition is indicated in blue. Error bars: group sd.
[0054] Fig. 12B . HTRA1 concentrations in posterior ocular tissues compared to aqueous humor (AH) in control (O) and LNA-treated (●) animals.
[0055] Fig.13 . Dynamics of HTRA1 concentration in aqueous humor.
[0056] Filled symbols: active treatment, empty symbols: excipient treatment.
[0057] Standardized value for an individual.
[0058] Fig.14 . Expression levels of HTRA1 mRNA in different compartments with and without LNA treatment. HTRA1 mRNA levels are shown as reads per kilobase per million sequencing reads (RPKM). Error bars represent standard deviations around the mean RPKM of at least 3 animals. Asterisks indicate statistical significance (false discovery rate < 0.05). Numbers above the bars show the percentage reduction in HTRA1 mRNA levels. DETAILED DESCRIPTION OF THE INVENTION
[0060] In the present specification, the term "alkyl", alone or in combination, means a straight or branched chain alkyl group having 1 to 8 carbon atoms, in particular a straight or branched chain alkyl group having 1 to 6 carbon atoms, more in particular a straight or branched chain alkyl group having 1 to 4 carbon atoms. Examples of straight and branched C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, isomeric pentyls, isomeric hexyls, isomeric heptyls and isomeric octyls, in particular methyl, ethyl, propyl, butyl and pentyl. Specific examples of alkyl are methyl, ethyl and propyl.
[0061] The term "cycloalkyl", alone or in combination, means a cycloalkyl ring having 3 to 8 carbon atoms, in particular a cycloalkyl ring having 3 to 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, more in particular cyclopropyl and cyclobutyl. A specific example of "cycloalkyl" is cyclopropyl.
[0062] The term "alkoxy", when used alone or in combination, means a radical of the formula alkyl-O-, wherein the term "alkyl" has the meaning given above, for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.butoxy and tert.butoxy. Particular "alkoxy" radicals are methoxy and ethoxy. Methoxyethoxy is a specific example of "alkoxyalkoxy".
[0063] The term "oxy", used alone or in combination, means an -O- group.
[0064] The term "alkenyl", alone or in combination, means a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 8, preferably up to 6, particularly preferably up to 4 carbon atoms. Examples of alkenyl groups are ethenyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl.
[0065] The term "alkynyl", alone or in combination, signifies a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 8, preferably up to 6 and particularly preferably up to 4 carbon atoms.
[0066] The term "halogen" or "halo", alone or in combination, means fluorine, chlorine, bromine or iodine, in particular fluorine, chlorine or bromine, more in particular fluorine. The term "halo", in combination with another group, means that the group is substituted with at least one halogen, in particular with one to five halogens, in particular with one to four halogens, i.e. one, two, three or four halogens.
[0067] The term "haloalkyl", alone or in combination, means an alkyl group substituted with at least one halogen, in particular an alkyl group substituted with one to five halogens, in particular one to three halogens. Examples of haloalkyl groups include monofluoro-, difluoro- or trifluoro-methyl, ethyl or propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl or trifluoromethyl. Fluoromethyl, difluoromethyl and trifluoromethyl are particular "haloalkyl groups".
[0068] The term "halocycloalkyl", alone or in combination, means a cycloalkyl group as defined above substituted with at least one halogen, in particular with one to five halogens, especially one to three halogens. Specific examples of "halocycloalkyl" are halocyclopropyl, in particular fluorocyclopropyl, difluorocyclopropyl and trifluorocyclopropyl.
[0069] The terms "hydroxy" and "hydroxyl", alone or in combination, refer to the -OH group.
[0070] The terms "thiol" and "thiol-containing", alone or in combination, refer to a -SH group.
[0071] The term "carbonyl", alone or in combination, signifies a -C(O)- group.
[0072] The term "carboxy" or "carboxyl", alone or in combination, means a -COOH group.
[0073] The term "amino", alone or in combination, means a primary amino group (-NH2), a secondary amino group (-NH-), or a tertiary amino group (-N-).
[0074] The term "alkylamino", alone or in combination, signifies an amino group as defined above substituted with one or two alkyl groups as defined above.
[0075] The term "sulfonyl", alone or in combination, means a -SO2 group.
[0076] The term "sulfinyl", alone or in combination, signifies a -SO- group.
[0077] The term "sulfanyl", alone or in combination, means a -S- group.
[0078] The term "cyano", alone or in combination, signifies a -CN group.
[0079] The term "azido", alone or in combination, means a -N3 group.
[0080] The term "nitro", alone or in combination, means a NO2 group.
[0081] The term "formyl", alone or in combination, signifies a -C(O)H group.
[0082] The term "carbamoyl", alone or in combination, signifies a -C(O)NH2 group.
[0083] The term "cabamido", alone or in combination, means a -NH-C(O)-NH2 group.
[0084] The term "aryl", alone or in combination, means a monovalent aromatic carbocyclic mono- or bicyclic ring system containing 6 to 10 carbon ring atoms, optionally substituted by 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of aryl include phenyl and naphthyl, in particular phenyl.
[0085] The term "heteroaryl", alone or in combination, means a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of heteroaryl groups include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolyl, isoquinolyl, quinazolinyl, quinoxaline, carbazolyl, or acridinyl.
[0086] The term "heterocyclyl", alone or in combination, means a monovalent saturated or partially unsaturated mono- or bicyclic ring system of 4 to 12 ring atoms, in particular 4 to 9 ring atoms, containing 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon, which is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, alkenyloxy, carboxyl, alkoxycarbonyl, alkylcarbonyl and formyl. Examples of monocyclic saturated heterocyclic groups are azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyranyl, 1,1-dihydrothiomorpholin-4-yl, 1,1-dioxo-thiomorpholin-4-yl, azcpanyl, diazepanyl, homopiperazinyl or oxazepanyl. Examples of bicyclic saturated heterocycloalkyl are 8-aza-bicyclo[3.2.1]octyl, quinuclidinyl, 8-oxa-3-azabicyclo[3.2.1]octyl, 9-aza-bicyclo[3.3.1]nonyl, 3-oxa-9-aza-bicyclo[3.3.1]nonyl or 3-thia-9-aza-bicyclo[3.3.1]nonyl. Examples of partially unsaturated heterocycloalkyl are dihydrofuranyl, imidazolinyl, dihydro-oxazolyl, tetrahydro-pyridinyl or dihydropyranyl.
[0087] The term "pharmaceutically acceptable salt" refers to those salts that retain the biological effectiveness and properties of free alkali or free acid, which are not undesirable biologically or otherwise. Salts are formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, particularly hydrochloric acid), and organic acids (e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine). In addition, these salts can be prepared by adding an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines (including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins). The oligonucleotides of the present invention may also exist in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of the present invention are salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.
[0088] The term "protecting group", alone or in combination, means a group that selectively blocks a reactive site in a multifunctional compound, thereby allowing a chemical reaction to be selectively performed at another unprotected reactive site. The protecting group can be removed. Exemplary protecting groups are amino protecting groups, carboxyl protecting groups or hydroxyl protecting groups.
[0089] A "hydroxy protecting group" is a protecting group for a hydroxy group and is also used to protect a thiol group. Examples of hydroxy protecting groups are acetyl (Ac), benzoyl (Bz), benzyl (Bn), β-methoxyethoxymethyl ether (MEM), dimethoxytrityl (or bis-(4-methoxyphenyl)phenylmethyl) (DMT), trimethoxytrityl (or tris-(4-methoxyphenyl)phenylmethyl) (TMT), methoxymethyl ether (MOM), methoxytrityl [(4-methoxyphenyl)diphenylmethyl] The hydroxy protecting group is hydroxyl protecting group. The hydroxy protecting group is hydroxyl protecting group. The hydroxy protecting group is hydroxyl protecting group. The hydroxy protecting group is hydroxyl protecting group. The hydroxy protecting group is hydroxyl protecting group. The hydroxy protecting group is hydroxyl protecting group.
[0090] If one of the starting materials or compounds of the present invention contains one or more functional groups that are unstable or reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups can be introduced before the key steps using methods well known in the art (such as TW Greene and PGM Wuts, 3rd edition, 1999, Wiley, New York, "Protective Groups in Organic Chemistry" as described). Such protecting groups can be removed at the later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butyloxycarbonyl (Boc), 9-fluorenylmethylcarbamate (Fmoc), 2-trimethylsilylethylcarbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).
[0091] The compounds described herein may contain several asymmetric centers and may exist as optically pure enantiomers, mixtures of enantiomers (eg, racemates), mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates.
[0092] An "effective amount" of an agent (eg, a pharmaceutical formulation) refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
[0093] Oligonucleotides
[0094] As used herein, the term "oligonucleotide" is defined as a molecule that is generally understood by the technician to contain two or more covalently linked nucleosides. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. Oligonucleotides are usually prepared in the laboratory by solid phase chemical synthesis and then purified. When referring to the sequence of an oligonucleotide, reference is made to the core base portion of the covalently linked nucleotides or nucleosides or the sequence or order of their modifications. Oligonucleotides are artificial, and are chemically synthesized, and are typically purified or separated. Oligonucleotides may contain one or more modified nucleosides or nucleotides.
[0095] The HTRA1 RNA antagonist mentioned in the present invention can be an oligonucleotide capable of regulating the expression of the HTRA1 target nucleic acid, such as siRNA or antisense oligonucleotide. Regulation by the HTRA1 RNA antagonist includes the ability to inhibit, downregulate, reduce, suppress, remove, stop, block, prevent, alleviate, reduce, avoid or terminate the expression of HTRA1, such as by mRNA degradation or transcription blocking, or via alternative splicing of HTRA1 pre-mRNA (splicing regulation of HTRA1 pre-mRNA).
[0096] siRNA and shRNA
[0097] In some embodiments, the HTRA1 mRNA antagonist is a siRNA or shRNA.
[0098] siRNA is a short double-stranded complex comprising a sense strand and an antisense strand, which together form a duplex region of 18-25 base pairs. The antisense strand of the siRNA targeting HTRA1 is complementary to the HTRA1 target nucleic acid (eg, HTRA1 mRNA). US2007185317 discloses siRNA targeting HTRA1.
[0099] Short hairpin RNA or small hairpin RNA (shRNA / hairpin vector) is an artificial RNA molecule with a tight hairpin-shaped turn that can be used to silence target gene expression via RNA interference (RNAi). The expression of shRNA in cells is usually accomplished by delivery of plasmids or through viral or bacterial vectors.
[0100] Antisense Oligonucleotides
[0101] Advantageously, the HTRA1 mRNA antagonist is an antisense oligonucleotide targeted to an HTRA1 nucleic acid.
[0102] The term "antisense oligonucleotide" as used herein is defined as an oligonucleotide that can regulate the expression of a target gene by hybridizing with a target nucleic acid, particularly hybridizing with a continuous sequence on the target nucleic acid in a cell expressing the target nucleic acid. Antisense oligonucleotides are not double-stranded substantially, and therefore are not siRNA or shRNAs. Preferably, the antisense oligonucleotide of the present invention is single-stranded. It should be understood that the single-stranded oligonucleotide of the present invention can form a hairpin or intermolecular duplex structure (a duplex between two molecules of the same oligonucleotide), as long as the degree of self-complementarity within or between them is less than 50% of the full-length oligonucleotide. The antisense oligonucleotide of the present invention is artificial, and is chemically synthesized, and is typically purified or separated. The antisense oligonucleotide of the present invention may include one or more modified nucleosides or nucleotides.
[0103] Continuous nucleotide region
[0104] The term "continuous nucleotide sequence" refers to the region where an oligonucleotide is complementary to a target nucleic acid. The term can be used interchangeably with the term "continuous core base sequence" and the term "oligonucleotide motif sequence" in this article. In some embodiments, all nucleotides of an oligonucleotide constitute a continuous nucleotide sequence. In some embodiments, an oligonucleotide comprises a continuous nucleotide sequence, such as a FGF' gapmer region, and may optionally comprise other nucleotides, such as a nucleotide joint region that can be used to connect a functional group to a continuous nucleotide sequence. The nucleotide joint region may or may not be complementary to a target nucleic acid.
[0105] Nucleotides
[0106] Nucleotide is the structural unit of oligonucleotide and polynucleotide, and for the purpose of the present invention, nucleotide includes naturally occurring and non-naturally occurring nucleotide. In nature, nucleotide, such as DNA and RNA nucleotide comprises ribose moiety, core base moiety and one or more phosphate groups (not present in nucleoside). Nucleoside and nucleotide can also be referred to as "unit" or "monomer" interchangeably.
[0107] Modified Nucleosides
[0108] The term "modified nucleoside" or "nucleoside modification" as used herein refers to a nucleoside modified by introducing one or more modifications of a sugar moiety or (core) base moiety compared to an equivalent DNA or RNA nucleoside. In a preferred embodiment, the modified nucleoside comprises a modified sugar moiety. The term modified nucleoside can also be used interchangeably with the term "nucleoside analog" or modified "unit" or modified "monomer" in this article. Nucleosides with unmodified DNA or RNA sugar moieties are referred to as DNA or RNA nucleosides in this article. If Watson Crick base pairing is allowed, nucleosides with modifications in DNA or RNA nucleobase regions are still generally referred to as DNA or RNA.
[0109] Modified internucleoside linkages
[0110] The term "modified internucleoside linkage" is defined as a linkage other than a phosphodiester (PO) linkage, which covalently couples two nucleosides together, as is commonly understood by the skilled artisan. Therefore, the oligonucleotides of the present invention may comprise modified internucleoside linkages. In some embodiments, modified internucleoside linkages increase the nuclease resistance of the oligonucleotides compared to phosphodiester linkages. For naturally occurring oligonucleotides, internucleoside linkages include phosphate groups that produce phosphodiester bonds between adjacent nucleosides. Modified internucleoside linkages are particularly useful for stabilizing oligonucleotides used in vivo, and can be used to prevent nuclease cleavage in regions of DNA or RNA nucleosides in the oligonucleotides of the present invention (such as within the gap (gap) region of gapmer oligonucleotides, and within regions of modified nucleosides, such as regions F and F').
[0111] In one embodiment, the oligonucleotide comprises one or more internucleoside linkages modified from natural phosphodiester, such as one or more modified internucleoside linkages that are more resistant to nuclease attack. Nuclease resistance can be determined by incubating the oligonucleotide in serum or by using a nuclease resistance assay (e.g., snake venom phosphodiesterase (SVPD)), both of which are well known in the art. Internucleoside linkages that can enhance the nuclease resistance of an oligonucleotide are referred to as nuclease-resistant internucleoside linkages. In some embodiments, at least 50% of the internucleoside linkages in an oligonucleotide or its continuous nucleotide sequence are modified, and in an oligonucleotide or its continuous nucleotide sequence, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80%, or such as at least 90%, the internucleoside linkages are nuclease-resistant internucleoside linkages. In some embodiments, all internucleoside linkages in an oligonucleotide or its continuous nucleotide sequence are nuclease-resistant internucleoside linkages. It should be recognized that in some embodiments, the nucleoside connecting the oligonucleotide of the present invention to a non-nucleotide functional group (such as a conjugate.) can be a phosphodiester.
[0112] A preferred modified internucleoside linkage for use in the oligonucleotides of the invention is phosphorothioate.
[0113] Phosphorothioate internucleoside connections are particularly useful due to nuclease resistance, beneficial pharmacokinetics and ease of manufacture. In some embodiments, at least 50% of the internucleoside connections in an oligonucleotide or its continuous nucleotide sequence are phosphorothioates, such as at least 60%, such as at least 70%, such as at least 75%, such as at least 80% or such as at least 90% of the internucleoside connections in an oligonucleotide or its continuous nucleotide sequence, are phosphorothioates. In some embodiments, all internucleoside connections of the oligonucleotide or its continuous nucleotide sequence are phosphorothioates. In some embodiments, the oligonucleotide of the present invention, in addition to comprising dithiophosphate connections, also comprises phosphorothioate internucleoside connections and at least one phosphodiester connection, such as 2,3 or 4 phosphodiester connections. In gapmer oligonucleotides, phosphodiester connections (when present) are appropriately not located between continuous DNA nucleosides in gap region G.
[0114] Nuclease-resistant linkages, such as phosphorothioate linkages, are particularly useful in regions of the oligonucleotide that are capable of recruiting nucleases when forming a duplex with a target nucleic acid, such as region G for a gapmer. However, phosphorothioate linkages can also be used in non-nuclease recruitment regions and / or affinity enhancement regions, such as the F and F' regions of a gapmer. In some embodiments, a gapmer oligonucleotide may comprise one or more phosphodiester linkages in region F or F', or both regions F and F', wherein all internucleoside linkages in region G may be phosphorothioates.
[0115] Advantageously, all internucleoside linkages in a contiguous nucleotide sequence of an oligonucleotide, or all internucleoside linkages of an oligonucleotide, are phosphorothioate linkages.
[0116] It is recognised that antisense oligonucleotides may comprise other internucleoside linkages (besides phosphodiester and phosphorothioate), such as alkylphosphonate / methylphosphonate internucleoside nucleotides, as disclosed in EP 2 742 135, which according to EP 2 742 135 may for example be tolerated in otherwise DNA phosphorothioate gap regions.
[0117] Nucleobase
[0118] The term core base includes purine (e.g., adenine and guanine) and pyrimidine (such as uracil, thymine and cytosine) moieties present in nucleosides and nucleotides, which form hydrogen bonds in nucleic acid hybridization. In the context of the present invention, the term core base also encompasses modified core bases, which may be different from naturally occurring core bases, but work during nucleic acid hybridization. In this article, "core base" refers to naturally occurring core bases, such as adenine, guanine, cytosine, thymine, uracil, xanthine and hypoxanthine, and non-naturally occurring variants. Such variants are, for example, described in Hirao et al. (2012) Accounts of Chemical Research, Vol. 45, p. 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1.
[0119] In some embodiments, the nucleobase moiety is modified by changing a purine or pyrimidine to a modified purine or pyrimidine, such as a substituted purine or substituted pyrimidine, such as a nucleobase selected from isocytosine, pseudoisocytosine, 5-methylcytosine, 5-thio-cytosine, 5-propynyl-cytosine, 5-propynyl-uracil, 5-bromouracil 5-thiazolopyrimidine, 2-thio-uracil, 2′thio-thymine, inosine, diaminopurine, 6-aminopurine, 2-aminopurine, 2,6-diaminopurine and 2-chloro-6-aminopurine.
[0120] The nucleobase moiety can be represented by the letter code for each corresponding nucleobase, for example, A, T, G, C or U, wherein each letter can optionally include a modified nucleobase having an equivalent function. For example, in an exemplary oligonucleotide, the nucleobase moiety is selected from A, T, G, C and 5-methylcytosine. Optionally, for LNA gapmers, 5-methylcytosine LNA nucleosides can be used.
[0121] Modified oligonucleotides
[0122] The term modified oligonucleotide describes an oligonucleotide comprising one or more sugar modified nucleosides and / or modified internucleoside linkages.The term "chimeric" oligonucleotide is a term that has been used in the literature to describe oligonucleotides with modified nucleosides.
[0123] Complementarity
[0124] The term "complementarity" describes the ability of the Watson-Crick base pairing of nucleosides / nucleotides. Watson-Crick base pairs are guanine (G)-cytosine (C) and adenine (A)-thymine (T) / uracil (U). It should be understood that oligonucleotides may include nucleosides with modified nucleobases, such as 5-methylcytosine is generally used instead of cytosine, and therefore, the term complementarity encompasses Watson-Crick base pairing base pairing between unmodified and modified nucleobases (see, e.g., Hirao et al. (2012) Accounts of Chemical Research Vol. 45, p. 2055 and Bergstrom (2009) Current Protocols in Nucleic Acid Chemistry Suppl. 37 1.4.1).
[0125] As used herein, the term "% complementary" refers to the ratio (expressed as a percentage) of nucleotides of a continuous nucleotide sequence in a nucleic acid molecule (e.g., an oligonucleotide) that is complementary to a reference sequence (e.g., a target sequence or sequence motif) across a continuous nucleotide sequence. Therefore, the percentage of complementarity is calculated by counting the number of nuclear bases that are complementary (Watson Crick base pairs) compared between the two sequences (when the oligonucleotide sequences of the target sequence 5'-3' and 3'-5' are aligned), dividing the number by the total number of nucleotides in the oligonucleotide, and then multiplying by 100. In this comparison, nuclear bases / nucleotides that are not aligned (do not form base pairs) are referred to as mismatches. When calculating the % complementarity of continuous nucleotide sequences, insertions and deletions are not allowed. It should be understood that when determining complementarity, as long as the functional ability of the nuclear bases forming Watson Crick base pairing is retained, there is no need to care about the chemical modification of the nuclear bases (e.g., for the purpose of calculating % identity, 5'-methylcytosine is considered to be the same as cytosine).
[0126] The term "fully complementary" refers to 100% complementarity.
[0127] Identity
[0128] As used herein, the term "identity" refers to the ratio (expressed as a percentage) of nucleotides of a continuous nucleotide sequence in a nucleic acid molecule (e.g., an oligonucleotide), which is consistent with a reference sequence (e.g., a sequence motif) across a continuous nucleotide sequence. Therefore, the percentage of identity is calculated by calculating the number of bases that are consistent (matched) between the two sequences compared (in the continuous nucleotide sequence of the compound of the invention and in the reference sequence), dividing the number by the total number of nucleotides in the oligonucleotide, and then multiplying by 100 to calculate. Therefore, the percentage of identity = (number of matches x 100) / length of the alignment region (e.g., a continuous nucleotide sequence). When calculating the percentage of identity of a continuous nucleotide sequence, insertions and deletions are not allowed. It should be understood that when determining identity, as long as the functional ability of the core bases to form Watson Crick base pairing is retained, there is no need to care about the chemical modification of the core bases (e.g., for the purpose of calculating % identity, 5'-methylcytosine is considered to be the same as cytosine).
[0129] Hybridization
[0130] As used herein, the term "hybridize" or "hybridization" is understood to mean that two nucleic acid strands (e.g., an oligonucleotide and a target nucleic acid) form hydrogen bonds between base pairs on opposite strands, thereby forming a duplex. The affinity of the binding between the two nucleic acid strands is the strength of the hybridization. The melting temperature (T m ), the melting temperature is defined as the temperature at which half of the oligonucleotides are duplexed with the target nucleic acid. Under physiological conditions, Tm is not strictly proportional to affinity (Mergny and Lacroix, 2003, Oligonucleotides 13: 515-537). The standard state Gibbs free energy ΔG° is a more accurate representation of binding affinity and is given by ΔG°=-RTln(K d ) and the dissociation constant (K d), where R is the gas constant and T is the absolute temperature. Therefore, the very low ΔG° of the reaction between the oligonucleotide and the target nucleic acid reflects the strong hybridization between the oligonucleotide and the target nucleic acid. ΔG° is the energy associated with the reaction with the following aqueous solution concentration of 1M, pH of 7, and temperature of 37°C. The hybridization of the oligonucleotide with the target nucleic acid is a spontaneous reaction, and for a spontaneous reaction, ΔG° is less than zero. ΔG° can be measured experimentally, for example, by using, for example, Hansen et al., 1965, Chem. Comm. 36-38 and Holdgate et al., 2005, isothermal titration calorimetry (ITC) described in Drug Discov Today. The technician will know that commercial equipment can be used for ΔG° measurement. ΔG° can also be numerically estimated using the nearest neighbor model described in SantaLucia, 1998, Proc Natl Acad Sci USA.95:1460-1465, using appropriately derived thermodynamic parameters described in Sugimoto et al., 1995, Biochemistry 34:11211-11216 and McTigue et al., 2004, Biochemistry 43:5388-5405. In order to have the possibility of modulating its intended nucleic acid target by hybridization, for oligonucleotides of 10-30 nucleotides in length, the oligonucleotides of the present invention hybridize to the target nucleic acid with an estimated ΔG° value of less than -10 kcal. In some embodiments, the degree or strength of hybridization is measured by the standard state Gibbs free energy ΔG°. For oligonucleotides of 8-30 nucleotides in length, the oligonucleotides can hybridize to the target nucleic acid with an estimated ΔG° value of less than -10 kcal (such as less than -15 kcal, such as less than -20 kcal and such as less than -25 keal). In some embodiments, the oligonucleotide hybridizes to the target nucleic acid with an estimated ΔG° value of about -10 to -60 kcal, such as -12 to -40, such as from -15 to -30 kcal or -16 to -27 kcal, such as -18 to -25 kcal.
[0131] Target sequence
[0132] As used herein, the term "target sequence" refers to the nucleotide sequence present in the target nucleic acid, which comprises a core base sequence complementary to the antisense oligonucleotide of the present invention. In some embodiments, the target sequence is composed of a region on the target nucleic acid, and the target nucleotide has a core base sequence complementary to the continuous nucleotide sequence of the antisense oligonucleotide of the present invention. This region of the target nucleic acid can be interchangeably referred to as a target nucleotide sequence, a target sequence or a target region. In some embodiments, the target sequence is longer than the continuous complementary sequence of a single oligonucleotide, and can for example represent a preferred region of the target nucleic acid that can be targeted by several oligonucleotides of the present invention.
[0133] The antisense oligonucleotides of the present invention comprise a contiguous nucleotide sequence that is complementary to a target nucleic acid, such as a target sequence described herein.
[0134] The target sequence complementary to the oligonucleotide generally comprises a continuous nucleobase sequence of at least 10 nucleotides. The continuous nucleotide sequence is between 10 and 50 nucleotides, such as 12 to 30, such as 14 to 20, such as 15 to 18 continuous nucleotides.
[0135] Target cells
[0136] As used herein, the term "target cell" refers to a cell expressing a target nucleic acid. In some embodiments, the target cell can be in vivo or in vitro. In some embodiments, the target cell is a mammalian cell, such as a rodent cell, such as a mouse cell, or a rat cell, or a primate cell, such as a monkey cell or a human cell.
[0137] High affinity modified nucleosides
[0138] A high affinity modified nucleoside is a modified nucleotide that, when incorporated into an oligonucleotide, can enhance the affinity of the oligonucleotide for its complementary target, such as by increasing the melting temperature (T m ). The high affinity modified nucleosides of the present invention preferably result in an increase in melting temperature of between +0.5 and +12°C per modified nucleoside, more preferably between +1.5 and +10°C, and most preferably between +3 and +8°C. Many high affinity modified nucleosides are known in the art, and include, for example, many 2' substituted nucleosides and locked nucleic acids (LNA) (see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curt. Opinion in Drug Development, 2000, 3(2), 293-213).
[0139] Sugar modification
[0140] The oligomers of the invention may comprise one or more nucleosides having a modified sugar moiety, ie, a modification of the sugar moiety as compared to the ribose sugar moiety found in DNA and RNA.
[0141] A number of nucleosides with modifications of the ribose sugar moiety have been prepared, primarily to improve certain properties of the oligonucleotide, such as affinity and / or nuclease resistance.
[0142] Such modifications include those in which the ribose ring structure is modified (such as by replacing with a hexose ring (HNA) or a dicyclo), which generally has a diradicle bridge (biradicle bridge) between the C2 and C4 carbons of a ribose ring (LNA), or generally lacks an unconnected ribose ring (such as UNA) of a key between a C2 and C3 carbon. Other sugar-modified nucleosides include, for example, bicyclohexose nucleic acids (WO2011 / 017521) or tricyclic nucleic acids (WO2013 / 154798). Modified nucleosides also include following nucleosides, wherein, for example, in the case of peptide nucleic acids (PNA) or morpholino nucleic acids, the sugar moiety is replaced by a non-sugar moiety.
[0143] 2' Modified Nucleosides.
[0144] 2' sugar modified nucleosides are nucleosides that have a substituent other than H or -OH at the 2' position (2' substituted nucleosides) or contain a 2' linked diradical capable of forming a bridge between the 2' carbon and the second carbon of the ribose ring, such as LNA (2'-4' diradical bridged) nucleosides.
[0145] In fact, much attention has been focused on the development of 2' substituted nucleosides, and it has been found that many 2' substituted nucleosides have beneficial properties when incorporated into oligonucleotides. For example, 2' modified sugars can provide enhanced binding affinity and / or increased nuclease resistance for oligonucleotides. Examples of 2' substituted modified nucleosides are 2'-O-alkyl-RNA, 2'-O-methyl-RNA, 2'-alkoxy-RNA, 2'-O-methoxyethyl-RNA (MOE), 2'-amino-DNA, 2'-fluoro-RNA and 2'-F-ANA nucleosides. For other examples, see, for example, Freier & Altmann; Nucl. Acid Res., 1997, 25, 4429-4443 and Uhlmann; Curr. Opinion in Drug Development, 2000, 3 (2), 293-213, and Deleavey and Damha, Chemistry and Biology 2012, 19, 937. Below are schematic representations of some nucleosides modified by 2' substitutions.
[0146]
[0147] With respect to the present invention, 2' substituted sugar modified nucleosides do not include 2' bridged nucleosides like LNA.
[0148] Locked Nucleic Acid (LNA)
[0149] "LNA nucleosides" are 2' modified nucleosides comprising a double radical at C2' and C4' linking the ribose sugar ring of the nucleoside (also called a "2'-4' bridge"), which constrains or locks the conformation of the ribose ring. These nucleosides are also referred to in the literature as bridged nucleic acids or bicyclic nucleic acids (BNA). When LNA is incorporated into an oligonucleotide of a complementary RNA or DNA molecule, the locking of the conformation of the ribose is associated with an enhanced affinity for hybridization (duplex stabilization). This can be routinely determined by measuring the melting temperature of the oligonucleotide / complementary duplex.
[0150] Without limitation, exemplary LNA nucleosides are disclosed in WO 99 / 014226, WO 00 / 66604, WO 98 / 039352, WO 2004 / 046160, WO 00 / 047599, WO 2007 / 134181, WO 2010 / 077578, WO 2010 / 036698, WO 2007 / 090071, WO 2009 / 006478, WO 2011 / 156202, WO 2008 / 154401, WO 2009 / 067647, WO 2008 / 150729, Morita et al., Bioorganic & Med. Chem. Lett. 12, 73-76, Seth et al. J. Org. Chem. 2010, Vol. 75(5) pp.1569-81, and Mitsuoka et al., Nucleic Acids Research 2009, 37(4), 1225-1238, and Wan and Seth, J. Medical Chemistry 2016, 59, 9645-9667.
[0151] Other non-limiting exemplary LNA nucleosides are disclosed in Scheme 1.
[0152] Scenario 1:
[0153]
[0154] Particular LNA nucleosides are β-D-oxy-LNA, 6'-methyl-β-D-oxy-LNA, such as (S)-6'-methyl-β-D-oxy-LNA (ScET) and ENA.
[0155] A particularly advantageous LNA, as used in the compounds of the examples, is β-D-oxy-LNA.
[0156] Activity and recruitment of RNase H
[0157] The RNase H activity of an antisense oligonucleotide refers to its ability to recruit RNase H when it forms a duplex with a complementary RNA molecule. WO01 / 23613 provides an in vitro method for determining RNase H activity, which can be used to determine the ability to recruit RNase H. Generally, an oligonucleotide is considered to be able to recruit RNase H if the following conditions are met: when provided with a complementary target nucleic acid sequence, the oligonucleotide has an initial rate measured in pmol / 1 / min of at least 5%, such as at least 10%, or 20% or more of the initial rate measured using an oligonucleotide (which has the same base sequence as the modified oligonucleotide being tested but contains only DNA monomers, and there are phosphorothioate linkages between all monomers in the oligonucleotide) and the method provided in Examples 91-95 of WO01 / 23613 (incorporated by reference). For the purpose of determining RNase H activity, recombinant human RNase H1 can be purchased from Lubio Science GmbH, Lucerne, Switzerland.
[0158] Gapmer
[0159] The antisense oligonucleotide, or a contiguous nucleotide sequence thereof, may be a gapmer. Antisense gapmers typically inhibit target nucleotides via RNase H-mediated degradation. Gapmer oligonucleotides contain at least three different structural regions in the '5→3' direction, the 5'-flank, the gap, and the 3'-flank, FGF'. The "gap" region (G) contains a stretch of contiguous DNA nucleotides that enable the oligonucleotide to recruit RNase H. The gap region is flanked by a 5'-flank region (F) containing one or more sugar-modified nucleosides, advantageously high-affinity sugar-modified nucleosides, and a 3'-flank region (F') containing one or more sugar-modified nucleosides, advantageously high-affinity sugar-modified nucleosides. One or more sugar-modified nucleosides in regions F and F' enhance the affinity of the oligonucleotide for the target nucleic acid (i.e., are affinity-enhanced sugar-modified nucleosides). In some embodiments, one or more sugar-modified nucleosides in regions F and F' are 2' sugar-modified nucleosides, such as high affinity 2' sugar modifications, such as independently selected from LNA and 2'-MOE.
[0160] In the gapmer design, the most 5' and 3' nucleosides of the gap region are DNA nucleosides, located near the sugar-modified nucleosides of the 5' (F) or 3' (F') regions, respectively. The flanks can also be defined by having at least one sugar-modified nucleoside at the ends farthest from the gap region, i.e., at the 5' end of the 5' flank and at the 3' end of the 3' flank.
[0161] The region FGF' forms a continuous nucleotide sequence. The antisense oligonucleotide of the present invention or its continuous nucleotide sequence may comprise a gapmer region of the formula FGF'.
[0162] The total length of the gapmer design FGF' can be, for example, 12 to 32 nucleosides, such as 13 to 24, such as 14 to 22 nucleosides, such as 14 to 17, such as 16 to 18 nucleosides.
[0163] For example, the gapmer oligonucleotide of the present invention can be represented by the following formula:
[0164] F 1-8 -G 5-16 -F′ 1-8 , such as
[0165] F 1-8 -G 7-16 -F′ 2-8
[0166] Provided that the total length of the gapmer region FGF' is at least 12, such as at least 14 nucleotides in length.
[0167] Regions F, G and F' are further defined below and may be incorporated into the FGF' formula.
[0168] Gapmer - Region G
[0169] The region G (gap region) of gapmer is the region of nucleosides, which enables oligonucleotides to recruit RNAaseH, such as human RNase H1, usually DNA nucleosides.RNaseH is a cellular enzyme that recognizes the duplex between DNA and RNA, and enzymatically cuts RNA molecules.Suitably, gapmer can have a length of at least 5 or 6 continuous DNA nucleosides, such as 5-16 continuous DNA nucleosides, such as 6-15 continuous DNA nucleosides, such as 7-14 continuous DNA nucleosides, such as 8-12 continuous DNA nucleotides, such as 8-12 continuous DNA nucleotides The gap region (G). In some embodiments, gap region G can be composed of 6,7,8,9,10,11,12,13,14,15 or 16 continuous DNA nucleosides.In some cases, the cytosine (C) DNA in the gap region may be methylated, and such residues are either marked as 5-methyl-cytosine ( me C or e in place of c). Methylation of the cytosine DNA in the gap is advantageous if a cg dinucleotide is present in the gap to reduce potential toxicity, and this modification has no significant effect on the efficacy of the oligonucleotide.
[0170] In some embodiments, the gap region G can consist of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 consecutive phosphorothioate-linked DNA nucleosides. In some embodiments, all internucleoside linkages in the gap are phosphorothioate linkages.
[0171] Although traditional gapmers have a DNA gap region, there are many examples of modified nucleosides that allow for RNase H recruitment when used within the gap region. Modified nucleosides that have been reported to be able to recruit RNase H when included within the gap region include, for example, alpha-L-LNA, C4′ alkylated DNA (as described in PCT / EP2009 / 050349 and Vester et al., Bioorg. Med. Chem. Lett. 18 (2008) 2296-2300, both incorporated herein by reference), arabinose-derivatized nucleosides such as ANA and 2′F-ANA (Mangos et al., 2003 J. AM. CHEM. SOC. 125, 654-661), UNA (unlocked nucleic acid) (as described in Fluiter et al., Mol. Biosyst., 2009, 10, 1039, incorporated herein by reference). UNA is an unlocked nucleic acid, typically a ribose in which the bond between C2 and C3 has been removed to form an unlocked "sugar" residue. The modified nucleosides used for such gapmers can be nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region, i.e., a modification that allows RNaseH recruitment). In some embodiments, the DNA gap region (G) described herein may optionally include 1 to 3 sugar-modified nucleosides that adopt a 2'endo (DNA-like) structure when introduced into the gap region.
[0172] Area G - "Gap-Destroyer"
[0173] Alternatively, there are many reports on inserting modified nucleosides that confer a 3' endo conformation into the gap region of the gapmer while retaining some RNaseH activity. Such gapmers having a gap region comprising one or more 3' endo-modified nucleosides are referred to as "gap-breakers" or "gap-destroyed" gapmers, see, for example, WO2013 / 022984. Gap-breaker oligonucleotides retain enough DNA nucleoside regions within the gap region to allow RNaseH recruitment. The ability of gap-breaker oligonucleotides to recruit RNaseH is typically sequence or even compound specific - see Rukov et al. 2015 Nucl.Acids Res.Vol.43 pp.8476-8487, which discloses "gap-breaker" oligonucleotides that recruit RNaseH that provide more specific cleavage of target RNA in certain cases. The modified nucleosides used in the gap region of the gap breaker oligonucleotide can be, for example, modified nucleosides that confer 3' endo conformation (confirmation), such as 2'-O-methyl (OMe) or 2'-O-MOE (MOE) nucleosides or β-D LNA nucleosides (the bridge between C2' and C4' of the ribose sugar ring of the nucleoside is in the β conformation), such as β-D-oxy LNA or ScET nucleosides.
[0174] As with the gapmer containing region G described above, the gap region of the gap destroyer or gap destroyed gapmer has a DNA nucleoside at the 5' end of the gap (adjacent to the 3' nucleoside of region F) and a DNA nucleoside at the 3' end of the gap (adjacent to the 5' nucleoside of region F'). Gapmers containing destroyed gaps typically retain a region of at least 3 or 4 consecutive DNA nucleosides at the 5' or 3' end of the gap region.
[0175] Exemplary designs of gap breaker oligonucleotides include
[0176] F 1-8 -[D 3-4 -E1-D 3-4 ]-F′ 1-8
[0177] F 1-8 -[D 1-4 -E1-D 3-4 ]-F′ 1-8
[0178] F 1-8 -[D 3-4 -E1-D 1-4 ]-F′ 1-8
[0179] The area G is in the square brackets [Dn -E r -D m ], D is a continuous sequence of DNA nucleosides, E is a modified nucleoside (a gap breaker or a gap-breaking nucleoside), and F and F′ are flanking regions as defined herein, provided that the total length of the gapmer region FGF′ is at least 12, such as at least 14 nucleotides in length.
[0180] In some embodiments, the region G of the gapmer of the gap destruction comprises at least 6 DNA nucleosides, such as 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 DNA nucleosides. As described above, the DNA nucleosides can be continuous or can be optionally interspersed with one or more modified nucleosides, provided that the gap region G is capable of mediating RNaseH recruitment.
[0181] Gapmer-flanking regions, F and F′
[0182] Region F is immediately adjacent to the 5' DNA nucleoside of region G. The 3'-most nucleoside of region F is a sugar-modified nucleoside, such as a high affinity sugar-modified nucleoside, for example a 2' substituted nucleoside, such as a MOE nucleoside or a LNA nucleoside.
[0183] Region F' is immediately adjacent to the 3' DNA nucleoside of region G. The 5'-most nucleoside of region F' is a sugar modified nucleoside, such as a high affinity sugar modified nucleoside, for example a 2' substituted nucleoside, such as a MOE nucleoside or a LNA nucleoside.
[0184] The length of region F is 1-8 consecutive nucleotides, such as 2-6, such as 3-4 consecutive nucleotides. Advantageously, the 5'most nucleoside of region F is a sugar-modified nucleoside. In some embodiments, the two 5'most nucleosides of region F are sugar-modified nucleosides. In some embodiments, the 5'most nucleosides of region F are LNA nucleosides. In some embodiments, the two 5'most nucleosides of region F are LNA nucleosides. In some embodiments, the two 5'most nucleosides of region F are 2'substituted nucleosides (nucleoside nucleosides), such as two 3'MOE nucleosides. In some embodiments, the 5'most nucleosides of region F are 2'substituted nucleosides, for example MOE nucleosides.
[0185] The length of region F' is 2-8 consecutive nucleotides, such as 3-6, for example, 4-5 consecutive nucleotides in length. Advantageously, in embodiments, the 3'most nucleoside of region F' is a sugar-modified nucleoside. In some embodiments, the two 3'most nucleosides of region F' are sugar-modified nucleosides. In some embodiments, the two 3'most nucleosides of region F' are LNA nucleosides. In some embodiments, the 3'most nucleosides of region F' are LNA nucleosides. In some embodiments, the two 3'most nucleosides of region F' are 2'substituted nucleosides (nucleoside nucleosides), such as two 3'MOE nucleosides. In some embodiments, the 3'most nucleosides of region F' are 2'substituted nucleosides, for example MOE nucleosides.
[0186] It should be noted that when region F or F' has a length of 1, it is advantageously an LNA nucleoside.
[0187] In some embodiments, regions F and F' independently consist of or include a continuous sequence of sugar-modified nucleosides. In some embodiments, the sugar-modified nucleosides of region F may be independently selected from 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, LNA units, arabinoic acid (ANA) units and 2'-fluoro-ANA units.
[0188] In some embodiments, regions F and F' independently comprise both LNA and 2' substituted modified nucleosides (mixed wing design).
[0189] In some embodiments, regions F and F' consist of only one type of sugar-modified nucleosides, such as only MOE or only β-D-oxy LNA or only ScET.Such a design is also referred to as a unified flank or unified gapmer design.
[0190] In some embodiments, all nucleosides of region F or F', or F and F' are LNA nucleosides, such as independently selected from β-D-oxy LNA, ENA or ScET nucleosides. In some embodiments, region F consists of 1-5, such as 2-4, such as 3-4, such as 1, 2, 3, 4 or 5 consecutive LNA nucleosides. In some embodiments, all nucleosides of regions F and F' are β-D-oxy LNA nucleosides.
[0191] In some embodiments, all nucleosides of region F or F', or F and F' are 2' substituted nucleosides, such as, for example, OMe or MOE nucleosides. In some embodiments, region F consists of 1, 2, 3, 4, 5, 6, 7 or 8 consecutive OMe or MOE nucleosides. In some embodiments, only one of the flanking regions can consist of 2' substituted nucleosides, such as OMe or MOE nucleosides. In some embodiments, it is the 5' (F) flanking region that consists of 2' substituted nucleosides, such as OMe or MOE nucleosides, and the 3' (F') flanking region comprises at least one LNA nucleoside, such as β-D-oxy LNA nucleosides or cET nucleosides. In some embodiments, it is the 3' (F') flanking region that consists of 2' substituted nucleosides, such as OMe or MOE nucleosides, and the 5' (F) flanking region comprises at least one LNA nucleoside, such as β-D-oxy LNA nucleosides or cET nucleosides.
[0192] In some embodiments, all modified nucleosides of regions F and F' are LNA nucleosides, such as independently selected from β-D-oxy LNA, ENA or ScET nucleosides, wherein region F or F', or F and F' may optionally contain DNA nucleosides (alternating flanks, see these definitions for more details). In some embodiments, all modified nucleosides of regions F and F' are β-D-oxy LNA, wherein region F or F', or F and F' may optionally contain DNA nucleosides (alternating flanks, see these definitions for more details).
[0193] In some embodiments, the 5'-most and 3'-most nucleosides of regions F and F' are LNA nucleosides, such as β-D-oxy LNA nucleosides or ScET nucleosides.
[0194] In some embodiments, the internucleoside linkage between region F and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between region F′ and region G is a phosphorothioate internucleoside linkage. In some embodiments, the internucleoside linkage between nucleosides of regions F or F′, F and F′ is a phosphorothioate internucleoside linkage.
[0195] Additional gapmer designs are disclosed in WO 2004 / 046160, WO 2007 / 146511 and WO 2008 / 113832, incorporated by reference.
[0196] LNA Gapmer
[0197] LNA gapmers are gapmers wherein one or both of regions F and F' comprise or consist of LNA nucleosides. β-D-oxy gapmers are gapmers wherein one or both of regions F and F' comprise or consist of β-D-oxy LNA nucleosides.
[0198] In some embodiments, the LNA gapmer has the formula: [LNA] 1-5 -[Region G]-[LNA] 1-5 , wherein region G is as defined in the definition of gapmer region G.
[0199] MOE Gapmer
[0200] MOE gapmers are gapmers in which regions F and F' consist of MOE nucleosides. In some embodiments, MOE gapmers are designed [MOE] 1-8 -[Region G]-[MOE] 1-8 , such as [MOE] 2-7 -[Area G] 5-16 -[MOE] 2-7 , such as [MOE] 3-6 -[Region G]-[MOE] 3-6 , wherein region G is defined as in the Gapmer definition. MOE gapmers (MOE-DNA-MOE) with a 5-10-5 design have been widely used in the art.
[0201] Hybrid Wing Gapmer
[0202] The hybrid wing gapmer is an LNA gapmer wherein one or both of regions F and F' comprises a 2' substituted nucleoside, such as a 2' substituted nucleoside independently selected from the group consisting of: 2'-O-alkyl-RNA units, 2'-O-methyl-RNA, 2'-amino-DNA units, 2'-fluoro-DNA units, 2'-alkoxy-RNA, MOE units, arabinonic acid (ANA) units and 2'-fluoro-ANA units, such as MOE nucleosides. In some embodiments, wherein at least one of regions F and F', or both regions F and F' comprise at least one LNA nucleoside, the remaining nucleosides of regions F and F' are independently selected from the group consisting of MOE and LNA. In some embodiments of hybrid wings, one or both regions F and F' may further comprise one or more DNA nucleosides.
[0203] Mixed-wing gapmer designs are disclosed in WO 2008 / 049085 and WO 2012 / 109395, which are hereby incorporated by reference.
[0204] Alternate Flanking Gapmer
[0205] The flanking regions may contain both LNA and DNA nucleosides and are referred to as "alternating flanks" because they contain an alternating motif of LNA-DNA-LNA nucleosides. Gapmers comprising such alternating flanks are referred to as "alternating flank gapmers". Thus, an "alternating flank gapmer" is an LNA gapmer oligonucleotide in which at least one flank (F or F') contains DNA in addition to LNA nucleosides. In some embodiments, at least one of regions F or F', or both regions F and F', contains both LNA nucleosides and DNA nucleosides. In such embodiments, the flanking regions F or F', or both F and F', contain at least three nucleosides, wherein the 5' and 3' most nucleosides of the F and / or F' regions are LNA nucleosides.
[0206] Alternating flank LNA gapmers are disclosed in WO 2016 / 127002.
[0207] Oligonucleotides with alternating flanks are LNA gapmer oligonucleotides, wherein at least one flank (F or F') comprises DNA in addition to LNA nucleosides. In some embodiments, at least one of regions F or F', or both regions F and F', comprises both LNA nucleosides and DNA nucleosides. In such embodiments, the flank regions F or F', or both F and F', comprise at least three nucleosides, wherein the 5' and 3' most nucleosides of the F and / or F' regions are LNA nucleosides.
[0208] In some embodiments, at least one of regions F or F', or both regions F and F', comprises both LNA nucleosides and DNA nucleosides. In such embodiments, the flanking regions F or F', or both F and F', comprise at least three nucleosides, wherein the 5' and 3' nucleosides of the F or F' region are LNA nucleosides. Flanking regions comprising both LNA and DNA nucleosides are referred to as alternating flanks because they comprise an alternating motif of LNA-DNA-LNA nucleosides. Alternating flank LNA gapmers are disclosed in WO2016 / 127002.
[0209] The alternating flanking regions may comprise up to 3 consecutive DNA nucleosides, such as 1 to 2 or 1 or 2 or 3 consecutive DNA nucleosides.
[0210] Alternate flanks can be annotated as a series of integers representing the number of LNA nucleosides (L) followed by the number of DNA nucleosides (D), e.g.
[0211] [L] 1-3 -[D] 1-4 -[L] 1-3
[0212] [L] 1-2 -[D] 1-2 -[L] 1-2 -[D] 1-2 -[L] 1-2
[0213] In oligonucleotide design, these will typically be represented numerically, such that 2-2-1 represents 5′[[L]2-[D]2-[L]3′, and 1-1-1-1-1 represents 5′[L]-[D]-[L]-[D]-[L]3′. The flank lengths (regions F and F′) in oligonucleotides with alternating flanks may independently be 3 to 10 nucleosides, such as 4 to 8, such as 5 to 6 nucleosides, such as 4, 5, 6 or 7 modified nucleosides. In some embodiments, only one flank in a gapmer oligonucleotide is alternating, while the other consists of LNA nucleotides. It may be advantageous to have at least two LNA nucleosides at the 3′ end of the 3′ flank (F′) to confer additional exonuclease resistance. Some examples of oligonucleotides with alternating flanks are:
[0214] [L] 1-5 -[D] 1-4 -[L] 1-3 -[G] 5-16 -[L] 2-6
[0215] [L] 1-2 -[D] 1-2 -[L] 1-2 -[D] 1-2 -[L] 1-2 -[G] 5-16 -[L] 1-2 -[D] 1-3 -[L] 2-4
[0216] [L] 1-5 -[G] 5-16 -[L]-[D]-[L]-[D]-[L]2
[0217] Provided that the total length of the gapmer is at least 12, such as at least 14 nucleotides in length.
[0218] Region D' or D" in an oligonucleotide
[0219] In some embodiments, the oligonucleotides of the present invention may comprise or consist of a contiguous nucleotide sequence of an oligonucleotide complementary to a target nucleic acid, such as a gapmer FGF' and additional 5' and / or 3' nucleosides. The additional 5' and / or 3' nucleosides may or may not be fully complementary to the target nucleic acid. Such additional 5' and / or 3' nucleosides may be referred to herein as regions D' and D".
[0220] The addition of region D′ or D″ can be used to link a contiguous nucleotide sequence, such as a gapmer, to a conjugate moiety or another functional group. When used to link a contiguous nucleotide sequence to a conjugate moiety, it can be used as a biocleavable linker. Alternatively, it can be used to provide exonuclease protection or ease of synthesis or manufacturing.
[0221] Regions D' and D" can be connected to the 5' end of region F or the 3' end of region F', respectively, to generate designs of the following formula: D'-FGF', FGF'-D" or
[0222] D'-FGF'-D". In this case, FGF' is the gapmer part of the oligonucleotide, while the region D' or D" constitutes a separate part of the oligonucleotide.
[0223] Region D′ or D″ may independently comprise or consist of 1, 2, 3, 4 or 5 additional nucleotides, which may be complementary or non-complementary to the target nucleic acid. The nucleotides adjacent to the F or F′ region are not sugar-modified nucleotides, such as DNA or RNA or base-modified forms of these. The D′ or D′ region may be used as a nuclease-sensitive, bio-cleavable linker (see definition of linker). In some embodiments, the additional 5′ and / or 3′ terminal nucleotides are linked to a phosphodiester linkage and are DNA or RNA. Nucleotide-based bio-cleavable linkers suitable for use as region D′ or D″ are disclosed in WO 2014 / 076195, which, for example, include phosphodiester-linked DNA dinucleotides. The use of bio-cleavable linkers in oligonucleotide constructs is disclosed in WO 2015 / 113922, where they are used to link multiple antisense constructs (e.g., gapmer regions) within a single oligonucleotide.
[0224] In one embodiment, the oligonucleotide of the present invention comprises a region D' and / or D" in addition to the continuous nucleotide sequence constituting the gapmer.
[0225] In some embodiments, the oligonucleotides of the invention can be represented by the following formula:
[0226] FGF′; especially F 1-8 -G 5-16 -F′ 2-8
[0227] D′-FGF′, especially D′ 1-3 -F 1-8 -G 5-16 -F′ 2-8
[0228] FGF′-D″, especially F 1-8 -G 5-16 -F′ 2-8 -D″ 1-3
[0229] D′-FGF′-D″, especially D′ 1-3 -F 1-8 -G 5-16 -F′ 2-8 -D″ 1-3
[0230] In some embodiments, the internucleoside linkage between region D' and region F is a phosphodiester linkage. In some embodiments, the internucleoside linkage between region F' and region D" is a phosphodiester linkage.
[0231] Conjugate
[0232] As used herein, the term conjugate refers to an oligonucleotide covalently linked to a non-nucleotide moiety (the conjugate moiety or region C or third region).
[0233] The conjugation of the oligonucleotide of the present invention with one or more non-nucleotide parts can improve the pharmacology of the oligonucleotide, for example, by affecting the activity, cellular distribution, cellular uptake or stability of the oligonucleotide. In some embodiments, the conjugate part changes or enhances the pharmacokinetic properties of the oligonucleotide by improving the cellular distribution, bioavailability, metabolism, excretion, permeability and / or cellular uptake of the oligonucleotide. In particular, the conjugate can target the oligonucleotide to a specific organ, tissue or cell type, thereby enhancing the effectiveness of the oligonucleotide in the organ, tissue or cell type. Meanwhile, the conjugate can be used to reduce the activity of the oligonucleotide in non-target cell types, tissues or organs, for example, off-target activity or activity in non-target cell types, tissues or organs. WO 93 / 07883 and WO2013 / 033230 provide suitable conjugate parts, which are hereby incorporated by reference. Other suitable conjugate parts are those that can be bound to asialoglycoprotein receptors (ASGPr). In particular, trivalent N-acetylgalactosamine conjugate moieties are suitable for conjugation to ASGPr, see for example WO 2014 / 076196, WO 2014 / 207232 and WO 2014 / 179620 (hereby incorporated by reference, in particular the Fig.13or claims 158-164 of WO2014 / 179620).
[0234] Oligonucleotide conjugates and their synthesis have been reported in the reviews by Manoharan, Antisense Drug Technology, Principles, Strategies, and Applications, ST Crooke, ed., Ch. 16, Marcel Dekker, Inc., 2001 and Manoharan, Antisense and Nucleic Acid Drug Development, 2002, 12, 103, each of which is incorporated herein by reference in its entirety.
[0235] In one embodiment, the non-nucleotide moiety (conjugate moiety) is selected from the group consisting of: a carbohydrate, a cell surface receptor ligand, a drug substance, a hormone, a lipophilic substance, a polymer, a protein, a peptide, a toxin (e.g., a bacterial toxin), a vitamin, a viral protein (e.g., a capsid), or a combination thereof.
[0236] Connectors
[0237] A connection or linker is a connection between two atoms that connects one chemical group or target fragment to another chemical group or target fragment by one or more covalent bonds. The conjugated moiety can be connected to the oligonucleotide directly or by a connecting moiety (e.g., a linker or tether). The linker is used to covalently link a third region, such as a conjugated moiety (region C), to a first region, such as an oligonucleotide or a continuous nucleotide sequence complementary to the target nucleic acid (region A), thereby connecting one of the ends of region A to C.
[0238] In some embodiments of the present invention, the conjugate or oligonucleotide conjugate of the present invention may optionally include a linker region (second region or region B and / or region Y) located between the oligonucleotide or continuous nucleotide sequence (region A or first region) complementary to the target nucleic acid and the conjugated part (region C or third region).
[0239] Region B refers to a bio-cleavable linker comprising or consisting of a physiologically unstable bond, which can be cleaved under conditions commonly encountered in mammals or under conditions similar thereto. The conditions under which the physiologically unstable linker undergoes chemical transformation (such as cleavage) include chemical conditions such as pH, temperature, oxidation or reduction conditions or reagents, and salt concentrations found in mammalian cells or similar salt concentrations encountered in mammalian cells. The intracellular conditions of mammals also include the presence of enzyme activities commonly present in mammalian cells, such as enzyme activities from proteolytic enzymes or hydrolytic enzymes or nucleases. In one embodiment, the bio-cleavable linker is sensitive to S1 nuclease cleavage. In a preferred embodiment, the nuclease-sensitive linker comprises 1 to 10 nucleosides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleosides, more preferably 2 to 6 nucleosides, most preferably 2 and 4 connected nucleosides, which comprise at least two consecutive phosphodiester connections, for example at least 3 or 4 or 5 consecutive phosphodiester connections. Preferably, the nucleoside is DNA or RNA. Phosphodiester containing biocleavable linkers are described in more detail in WO 2014 / 076195 (hereby incorporated by reference).
[0240] The conjugate can also be connected to the oligonucleotide through a non-bio-cleavable linker, or in some embodiments, the conjugate can include a non-cleavable linker (region Y) covalently linked to a bio-cleavable linker. The linker is not necessarily bio-cleavable, but is mainly used to covalently link the conjugate portion (region C or the third region) to the oligonucleotide (region A or the first region), and can include an oligomer of a chain structure or repeating unit (e.g., ethylene glycol, an amino acid unit or an aminoalkyl group). The oligonucleotide conjugate of the present invention can be constructed by the following regional elements: AC, ABC, ABYC, AYBC or AYC. In some embodiments, the non-cleavable linker (region Y) is an aminoalkyl group, such as a C2-C36 aminoalkyl group, including such as a C6 to C12 aminoalkyl group. In a preferred embodiment, the linker (region Y) is a C6 aminoalkyl group. The conjugate linker group can be conventionally attached to the oligonucleotide by using an amino-modified oligonucleotide and an activated ester group on the conjugate group.
[0241] HTRA1
[0242] As used herein, the term "HTRA1" refers to any native, primate or human high temperature demand A1 protein from any mammal, such as from any mammalian source, including primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses "full length," unprocessed HTRA1 as well as any form of HTRA1 produced by processing in cells. The term also encompasses naturally occurring variants of HTRA1, such as splice variants or allelic variants. The UniProt accession number for human HTRA1 is Q92743. The amino acid sequence of an exemplary human HTRA1 is shown in SEQ ID NO: 1.
[0243] SEQ ID NO 1:
[0244]
[0245] An exemplary primate HTRA1 amino acid sequence is shown in SEQ ID NO: 2 (Macaca fascicularis). The Macaca mulatta HTRA1 amino acid sequence is disclosed in Uniprot Accession No. H9FX91.
[0246] SEQ ID NO 2
[0247]
[0248] HTRA1 is also known in the art as protease, serine, 11 (IGF binding) (PRSS11), ARMD7, HtrA, and IGFBP5-protease. The term "HTRA1" also encompasses "HTRA1 variants," which refers to active HtrA1 polypeptides having at least about 90% amino acid sequence identity with a native sequence HtrA1 polypeptide, such as SEQ ID NO: 1 or SEQ ID NO 2. Typically, HTRA1 variants will have at least about 95% amino acid sequence identity, or at least about 98% amino acid sequence identity, or at least about 99% amino acid sequence identity with a native HTRA1 sequence (e.g., SEQ ID NO: 1 or SEQ ID NO 2).
[0249] The term "HTRA1 mRNA antagonist" is used to refer to an HTRA1 antagonist that targets an HTRA1 nucleic acid, such as an mRNA, including an HTRA1 mRNA or a pre-mRNA. In some embodiments, the HTRA1 mRNA antagonist is an antisense oligonucleotide or siRNA and shRNA or a ribozyme.
[0250] HTRA1 mRNA antagonists are capable of inhibiting the expression of HTRA1 target nucleic acids in cells expressing HTRA1 target nucleic acids. Advantageously, the HTRA1 mRNA antagonists are oligonucleotides or include oligonucleotides, wherein the continuous sequence of the nucleobases of the oligonucleotides is complementary to the HTRA1 target nucleic acid, such as fully complementary, as measured across the length of the oligonucleotide or its continuous nucleotide sequence. In some embodiments, the HTRA1 target nucleic acid can be RNA or DNA, such as messenger RNA, such as mature mRNA or precursor mRNA. In some embodiments, the target nucleic acid is an RNA encoding a mammalian HTRA1 protein (such as human HTRA1), for example a human HTRA1 mRNA sequence, such as disclosed in SEQ ID NO 3 or 4. Tables 1 and 2 provide more information about exemplary target nucleic acids.
[0251] Table 1. Genomic and assembly information of human and cynomolgus monkey HTRA1.
[0252]
[0253] Fwd = forward strand. Genomic coordinates provide the pre-mRNA sequence (genomic sequence). NCBI reference provides the mRNA sequence (cDNA sequence).
[0254] *The National Center for Biotechnology Information Reference Sequence Database is a comprehensive, complete, non-redundant, and fully annotated reference sequence database, including genomes, transcripts, and proteins. It is located at www.ncbi.nlm.nih.gov / refseq.
[0255] ** In the NCBI reference sequence, there is a stretch of 100 nucleotides from position 126 to position 227, the identity of which is unknown. In SEQ ID NOs 5 & 6, this stretch has been replaced by the nucleotides present in the human and macaque (Macaca mulatta) HTRA1 pre-mRNA sequences in this region.
[0256] Table 2. Sequence details of human and cynomolgus monkey HTRA1.
[0257]
[0258] Oligonucleotide antagonists of HTRA1
[0259] PCT / EP2017 / 065937 and EP17173964.2, which are incorporated herein by reference in their entirety, disclose a number of antisense oligonucleotides that are potent in vivo inhibitors of HTRA1 mRNA and their therapeutic uses, including for the treatment of macular degeneration, which may be used in the present invention.
[0260] The HTRA1 mRNA antagonist may be an antisense oligonucleotide or siRNA comprising a contiguous nucleotide sequence of 10-30 nucleotides in length having at least 90% complementarity (such as fully complementary) to a mammalian HTRA1 nucleic acid, such as SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5 or SEQ ID NO 6.
[0261] Advantageously, the HTRA1 mRNA antagonist is an LNA antisense oligonucleotide, such as an LNA gapmer oligonucleotide.
[0262] In some embodiments, the HTRA1 mRNA antagonist, such as an antisense oligonucleotide, including an LNA antisense oligonucleotide or a gapmer oligonucleotide, comprises a contiguous nucleotide region of 10-22 nucleotides that is at least 90%, such as 100%, complementary to SEQ ID NO 7:
[0263] SEQ ID NO 7: 5′CCAACAACCAGGTAAATATTTG 3′
[0264] In some embodiments, the HTRA1 mRNA antagonist, such as an antisense oligonucleotide or siRNA; such as an LNA antisense oligonucleotide or a gapmer oligonucleotide, comprises a region of contiguous nucleotides of at least 12 contiguous nucleotides in length present in a sequence selected from the group consisting of:
[0265] SEQ ID NO 8:CAAATATTTACCTGGTTG
[0266] SEQ ID NO9: TITACCTGGTTGTTGG
[0267] SEQ ID NO 10: CCAAATATTTAACCTGGTT
[0268] SEQ ID NO 11: CCAAATATTTACCTGGGTTGT
[0269] SEQ ID NO 12: ATATTTTACCTGGGTTGTTG
[0270] SEQ ID NO13: TATTTAACCTGGTTGTT
[0271] SEQ ID NO 14: ATATTTACCTGGGTTGT, and
[0272] SEQ ID NO 15: ATATTTTACCTGGTTGTT.
[0273] In some embodiments, the HTRA1 mRNA antagonist (antisense oligonucleotide) is or comprises an oligonucleotide selected from the group consisting of:
[0274] C s A s A s A s t s a s t s t s t s a s c s c s t s g s G s T s T s G (SEQ ID NO 8, compound #8, 1)
[0275] T s T s t s a s c s c s t s g s g s t s t s g s t s T s G s G (SEQ ID NO 9, compound #9, 1)
[0276] C s C s A s A s a s t s a s t s t s t s a s c s c s t s g s G s T sT(SEQ ID NO 10, Compound #10, 1)
[0277] C s C s A s a s a s t s a s t s t s t s a s c s c s t s g s g s t s t s G s T(SEQ ID NO 11, Compound #11, 1)
[0278] A s T s A s t s t s t s a s c s C s t s g s g s t s t s g s T s T s G(SEQ ID NO 12, Compound #12, 1)
[0279] T s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T(SEQ ID NO 13, Compound #13, 1)
[0280] T s A s t s t s t s a s cs c s t s g s G s t s T s g s T s T (SEQ ID NO 13, Compound #13, 2)
[0281] T s A s T s t s t s a s c s c s t s g s g s T s T s g s T s T (SEQ ID NO 13, Compound #13, 3)
[0282] A s T s A s T s t s t s a s c s c s t s g s g s T s T s G s T (SEQ ID NO 14, Compound #14, 1)
[0283] A s t s A s T s T s t s a s c s c s t s g s g s t s T s G s T (SEQ ID NO 14, Compound #14, 2)
[0284] A s t s A s Ts t s t s a s c s c S t s g s G s T s T s g s T s T (SEQ ID NO 15, Compound #15, 1)
[0285] A s T s A s t s t s t s a s c s c s t s g s G s t s T s g s T s T (SEQ ID NO 15, Compound #15, 2)
[0286] A s t s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T (SEQ ID NO 15, Compound #15, 3)
[0287] The capital letters represent β-D-oxy LNA nucleoside units, the lowercase letters represent DNA nucleoside units, the subscript s represents phosphorothioate internucleoside linkages, and all LNA cytosines are 5-methylcytosine.
[0288] In some embodiments, the HTRA1 mRNA antagonist is or comprises the formula 5'T s A s T s t s t s a s c sc s t s g s g s t s T s G s T s T 3' (SEQ ID NO 13) or 5' A s t s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T3' (SEQ ID NO 15), wherein capital letters represent β-D-oxy LNA nucleoside units, lowercase letters represent DNA nucleoside units, subscript s represents phosphorothioate internucleoside linkages, and wherein all LNA cytosines are 5-methylcytosine or a pharmaceutically acceptable salt thereof.
[0289] In some embodiments, the antisense oligonucleotide is 10-30 nucleotides in length, wherein the antisense oligonucleotide targets an HTRA1 nucleic acid and comprises a contiguous nucleotide region of 10-22 nucleotides that is at least 90% (such as 100%) complementary to SEQ ID NO 16.
[0290] SEQ ID NO 16:
[0291]
[0292] In some embodiments, the antisense oligonucleotide is or comprises a region of contiguous nucleotides selected from any one of SEQ ID NOs 17, 18 and 19, or at least 12 contiguous nucleotides thereof:
[0293] CTTCTCTATCTACGCAT(SEQ ID NO 17)
[0294] TACTTTAATAGCTCAA(SEQ ID NO 18)
[0295] TTCTATCTACGCATTG(SEQ ID NO 19)
[0296] In some embodiments, the antisense oligonucleotide is or comprises a region of contiguous nucleotides selected from:
[0297] CTTCttctatctacgcAT (SEQ ID NO 17),
[0298] TACTttaatagcTCAA (SEQ ID NO 18), and
[0299] TTCtatctacgcaTTG(SEQ ID NO 19);
[0300] wherein upper case letters are LNA nucleotides, lower case letters are DNA nucleosides, and the cytosine residue is optionally 5-methylcytosine.
[0301] In some embodiments, the antisense oligonucleotide is or comprises a region of contiguous nucleotides selected from:
[0302] m C s T s T s m C s t s t s c s t s a s t s c s t s a s m c s g s c s A s T (SEQ ID NO 17, C ID #17),
[0303] T s A s m C s T s t s t s a s a s t s a s g s c s T s m C s A s A (SEQ ID NO 18, C ID #18),
[0304] T s T s m C s ts a s t s c s t s a s m c s g s c s a s T s T s G (SEQ ID NO 19, C ID #19),
[0305] Wherein capital letters represent β-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, the subscript s represents phosphorothioate internucleoside linkages, and m C represents 5-methylcytosine β-D-oxy LNA nucleoside, and m c represents 5-methylcytosine DNA nucleoside.
[0306] Exemplary LNA antisense oligonucleotide compounds are described in Figure 1 , 2 , 3, 4 and 5, which are HTRA1 mRNA antagonists for use according to the invention or in accordance with the method of the invention.
[0307] Eye and HTRA1-related disorders
[0308] As used herein, the term "HtrA1-related disorder" refers broadly to any disorder or condition associated with HtrA1 expression or activity, including abnormal HTRA1 expression or activity. In some embodiments, the HTRA1-related disorder is associated with excessive HTRA1 levels or activity, wherein atypical symptoms may manifest due to the level or activity of HTRA1 locally (e.g., in the eye) and / or systemically in the body. Exemplary HTRA1-related disorders include HTRA1-related ocular disorders, which include, but are not limited to, for example, age-related macular degeneration (AMD), including wet (exudative) AMD (including early, intermediate, and late wet AMD) and dry (non-exudative) AMD (including early, intermediate, and late dry AMD (e.g., geographic atrophy (GA)).
[0309] As used herein, the term "ocular disorder" includes, but is not limited to, disorders of the eye, including macular degenerative diseases, such as age-related macular degeneration (AMD), including wet (exudative) AMD (including early, intermediate and late wet AMD) and dry (non-exudative) AMD (including early, intermediate and late dry AMD (e.g., geographic atrophy (GA); diabetic retinopathy (DR)) and other ischemia-related retinopathies; endophthalmitis; uveitis; choroidal neovascularization (CNV); retinopathy of prematurity (ROP); polypoidal choroidal vasculopathy (PCV); diabetic macular edema; pathological myopia; von Hippel-Lindau disease; ocular histoplasmosis; central retinal vein occlusion (CRVO); corneal neovascularization and retinal neovascularization. In some embodiments, the ocular disorder is AMD (e.g., GA).
[0310] Subjects
[0311] An "individual" or "subject" is a mammal. Mammals include primates (e.g., humans and non-human primates such as monkeys) and rodents (e.g., mice and rats). In certain embodiments, an individual or subject is a human. A "subject" may be a "patient" - a patient is a human subject in need of treatment, may be an individual with an HTRA1-related disorder such as an eye disorder, a subject at risk of developing an HTRA1-related disorder such as an eye disorder.
[0312] In some embodiments, the patient is a person who has been diagnosed with an ocular condition, such as those listed herein, such as an ocular condition selected from AMD, diabetic retinopathy, retinopathy of prematurity, or polypoidal choroidal vasculopathy. In some embodiments, the ocular condition is selected from early dry AMD, mid-term dry AMD, or late dry AMD. In some embodiments, the ocular condition is geographic atrophy.
[0313] In some embodiments, the patient is a person who has been identified as being at risk of developing an eye condition, such as those listed herein, such as an eye condition selected from AMD, diabetic retinopathy, retinopathy of prematurity, or polypoidal choroidal vasculopathy. In some embodiments, the eye condition is selected from early dry AMD, mid-term dry AMD, or late dry AMD. In some embodiments, the eye condition is geographic atrophy.
[0314] In some embodiments, the patient is a human having elevated levels of HTRA1 in their aqueous humor or vitreous humor. In some embodiments, the patient is a human who has been diagnosed with an HTRA1-related disorder or has been identified as being at risk of developing an HTRA1-related disorder. Thus, the patient may be a subject who has elevated levels of HTRA1 in their aqueous humor or vitreous humor (optionally may be asymptomatic).
[0315] In some embodiments, the patient may be a subject having one or more disease-associated polymorphisms in the HTRA1 gene or HTRA1 control sequence, such as the HTRA1 promoter polymorphism rs11200638 (G / A) (see, e.g., DeWan et al., Science 314:989-992, 2006, which is incorporated herein by reference in its entirety). Thus, the patient may be a subject having a disease-associated polymorphism in its HTRA1 gene or HTRA1 control sequence, and optionally may be asymptomatic.
[0316] Medicinal salt
[0317] For use as a therapeutic agent, the HTRA1 mRNA antagonist used according to the methods or uses of the invention, such as an oligonucleotide targeting HTRA1, may be provided as a suitable pharmaceutical salt such as a sodium salt or a potassium salt. In some embodiments, the oligonucleotide of the invention is a sodium salt.
[0318] Pharmaceutical composition
[0319] On the other hand, the present invention provides a pharmaceutical composition comprising any of the above oligonucleotides and / or oligonucleotide conjugates and a pharmaceutically acceptable diluent, carrier, salt and / or adjuvant. Pharmaceutically acceptable diluents include phosphate buffered saline (PBS), and pharmaceutically acceptable salts include but are not limited to sodium salts and potassium salts. In some embodiments, the pharmaceutically acceptable diluent is sterile phosphate buffered saline. In some embodiments, the oligonucleotide is used in a pharmaceutically acceptable diluent at a concentration of 50-300 μM solution. In some embodiments, the oligonucleotide of the present invention is administered at a dosage of 10-1000 μg.
[0320] WO 2007 / 031091 provides suitable and preferred examples of pharmaceutically acceptable diluents, carriers and adjuvants (hereby incorporated by reference). WO 2007 / 031091 also provides suitable dosages, formulations, routes of administration, compositions, dosage forms, combinations with other therapeutic agents, and prodrug formulations.
[0321] The oligonucleotide or oligonucleotide conjugate of the present invention can be mixed with pharmaceutically acceptable active or inert substances for preparing pharmaceutical compositions or formulations. The composition and method for preparing the pharmaceutical composition depends on many criteria, including but not limited to the route of administration, the extent of the disease or the dosage administered.
[0322] In some embodiments, the oligonucleotide or oligonucleotide conjugate of the invention is a prodrug. In particular, for oligonucleotide conjugates, once the prodrug is delivered to the site of action, such as a target cell, the conjugate portion is cleaved from the oligonucleotide.
[0323] Application
[0324] The HTRA1 mRNA antagonist may be administered topically (such as to the skin, by inhalation, via the eye or via the ear) or enterally (such as orally or via the gastrointestinal tract) or parenterally (such as intravenously, subcutaneously, intramuscularly, intracerebrally, intracerebroventricularly or intrathecally).
[0325] In some embodiments, the HTRA1 mRNA antagonist is administered by a parenteral route, including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, intrathecal or intracranial, such as intracerebral or intraventricular administration. In some embodiments, the active oligonucleotide or oligonucleotide conjugate is administered intravenously. In another embodiment, the active oligonucleotide or oligonucleotide conjugate is administered subcutaneously.
[0326] For use in treating ocular disorders, HTRA1 mRNA antagonists, such as the LNA oligonucleotides described herein, can be injected intraocularly.
[0327] In some embodiments, the compound of the invention or a pharmaceutically acceptable salt thereof is administered by intraocular injection at a dose of about 10 μg to about 200 μg per eye, such as about 50 μg to about 150 μg per eye, such as about 100 μg per eye. In some embodiments, the dosage interval, i.e., the time period between consecutive administrations, is at least monthly, such as at least every two months or at least every three months.
[0328] Determination of HTRA1 levels in samples
[0329] A sample of vitreous or aqueous humor, advantageously a sample of aqueous humor, is obtained from the subject.The level of HTRA1 present in the sample may be determined by any method known in the art, suitably via the use of anti-HTRA1 antibodies in an immunoassay or via the use of mass spectrometry.
[0330] In some embodiments, HTRA1 protein levels are determined using mass spectrometry.
[0331] In some embodiments, the level of HTRA1 protein is determined using an immunoassay, such as using an HTRA1-specific antibody.
[0332] In some embodiments, HTRA1 protein levels are captured using HTRA1 antibodies and then determined by LC-MS.
[0333] In some embodiments, HTRA1 protein levels are determined via LC-MS of a protease, such as trypsin, from a digested protein sample of immunocaptured HTRA1 obtained from a sample of vitreous or aqueous humor from a subject. Other proteases that can be used to digest immunocaptured HTRA1 include LysC, AspN, GluC.
[0334] In some embodiments, HTRA1 antibodies are used to immunocapture HTRA1 protein from a sample, for example, via an immunocapture enzyme-linked immunosorbent assay (ELISA) or via Western blot.
[0335] Comparing the level of HTRA1 to one or more reference samples
[0336] As described above, HTRA1 overexpression is associated with many eye diseases, including AMD such as early dry AMD, intermediate dry AMD or late dry AMD such as geographic atrophy. Therefore, in step ii), the method of the present invention may include comparing the HTRA1 level (e.g., HTRA1 protein level) obtained in step i) with one or more reference values of HTRA1 levels in healthy subjects (negative control subjects), or an average or mean reference value obtained from a population of such healthy subjects (negative control subjects), wherein the healthy subjects do not suffer from an eye disease or do not have a disease-associated polymorphism in the HTRA1 gene (including the HTRA control region). Alternatively or in addition, step ii) may include comparing the HTRA1 level (e.g., HTRA1 protein level) obtained in step ii) with one or more reference values of HTRA1 levels in a subject, wherein the subject has been diagnosed with an HTRA1-associated eye disease, or has been characterized as overexpressing HTRA1, and / or has been characterized as having a disease-associated polymorphism in the HTRA1 gene (including the HTRA control region) - i.e., a positive control. HTRA1 levels that are elevated compared to a negative control subject and / or similar or equal to a positive control value are an indication that the subject may be or is suitable for treatment with an HTRA1 mRNA antagonist.
[0337] In another embodiment, in addition to the positive and / or negative control values, the values previously obtained from the same individual subject can also be used. Therefore, the reference sample can include one or more historical values previously obtained from the same subject. By comparing the HTRA1 level obtained in step i) with the historical values from the same subject, the efficacy of HTRA1 mRNA antagonist treatment can be monitored, and therefore can be used to determine the possible effective dose of HTRA1 mRNA antagonist. In this regard, in some embodiments, the purpose of HTRA1 mRNA antagonist treatment is to substantially normalize HTRA1 levels rather than achieve complete inhibition. Therefore, the method or use of the present invention can be used for patient monitoring of HTRA1 levels before, during or after HTRA1 treatment, and can be used, for example, between the administration doses of HTRA1 mRNA antagonists, such as allowing for adjustment of dosage to optimize the therapeutic effect.
[0338] Other embodiments of the present invention
[0339] 1. A method for determining the suitability of a subject for treatment with an HTRA1 mRNA antagonist, the method comprising the steps of:
[0340] i) determining the level of HTRA1 in a sample of aqueous humor or vitreous humor obtained from the subject
[0341] ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values;
[0342] to determine whether the subject is likely or suitable for treatment with an HTRA1 mRNA antagonist,
[0343] wherein the subject suffers from or is at risk of developing an ocular disorder such as macular degeneration.
[0344] 2. The method according to embodiment 1, wherein the level of HTRA1 in the sample of aqueous humor or vitreous humor is determined by quantifying the level of HTRA1 protein in the sample.
[0345] 3. The method according to embodiment 2, wherein the level of HTRA1 protein is determined using an immunoassay such as using an HTRA1-specific antibody.
[0346] 4. The method according to embodiment 3, wherein the level of HTRA1 protein is determined using mass spectrometry, for example via HTRA1 antibody capture followed by LC-MS.
[0347] 5. A method according to any one of embodiments 1-4, wherein at least one of the reference samples or reference values is obtained from a control subject suffering from macular degeneration.
[0348] 6. A method according to any one of embodiments 1-5, wherein at least one of the reference samples or reference values is obtained from a control subject suffering from macular degeneration.
[0349] 7. A method according to any one of embodiments 1-6, wherein at least one of the reference samples is a value previously obtained from the same subject whose suitability for treatment is being assessed.
[0350] 8. The method according to any one of embodiments 1-7, wherein the reference value is derived from a data set that models the correlation between the HTRA1 concentration in the retina and the HTRA1 concentration in the aqueous humor or vitreous humor.
[0351] 9. The method according to any one of claims 1 to 8, wherein the HTRA1 mRNA antagonist is selected from the group consisting of: antisense oligonucleotides targeting HTRA1 mRNA or pre-mRNA, siRNA targeting HTRA1 mRNA, ribozymes targeting HTRA1 mRNA or pre-mRNA.
[0352] 10. The method of any one of embodiments 1-9, wherein the method is used to determine whether the subject has enhanced expression of HTRA1 mRNA or HTRA1 protein in the retina, such as in retinal epithelial cells.
[0353] 11. A method according to any one of embodiments 1-10, wherein the subject has or is at risk of developing an eye condition selected from the group consisting of: macular degeneration diseases, such as age-related macular degeneration (AMD), including wet (exudative) AMD (including early, intermediate and late wet AMD) and dry (non-exudative) AMD (including early, intermediate and late dry AMD (such as geographic atrophy (GA)); diabetic retinopathy (DR) and other ischemia-related retinopathies; endophthalmitis; uveitis; choroidal neovascularization (CNV); retinopathy of prematurity (ROP); polypoidal choroidal vasculopathy (PCV); diabetic macular edema; pathological myopia; von Hippel-Lindau disease; ocular histoplasmosis; central retinal vein occlusion (CRVO); corneal neovascularization and retinal neovascularization.
[0354] 12. A method according to any one of embodiments 1-11, wherein the subject suffers from or is at risk of developing age-related macular degeneration (AMD), such as the AMD is selected from the group consisting of: wet (exudative) AMD (including early, intermediate and late wet AMD), dry (non-exudative) AMD (including early, intermediate and late dry AMD (e.g., geographic atrophy (GA)); advantageously dry AMD.
[0355] 13. The method according to any one of embodiments 1-12, wherein the method is used to determine a suitable dosage regimen for administering an HTRA1 mRNA antagonist.
[0356] 14. The method according to any one of embodiments 1-13, wherein the HTRA1 mRNA antagonist is an oligonucleotide comprising a contiguous nucleotide region of 10-30 nucleotides that is fully complementary to an HTRA1 target nucleic acid sequence such as SEQ ID NO 1 or SEQ ID NO 2.
[0357] 15. The method according to any one of embodiments 1-14, wherein the HTRA1 mRNA antagonist is or comprises an oligonucleotide comprising a contiguous nucleotide sequence of at least 12 nucleotides in length, which is at least 90% complementary to SEQ ID NO 7 or SEQ ID NO 16, such as fully complementary.
[0358] 16. The method according to any one of embodiments 1-15, wherein the HTRA1 mRNA antagonist is or comprises an antisense oligonucleotide, such as an LNA gapmer oligonucleotide.
[0359] 17. The method according to any one of embodiments 1-16, wherein the HTRA1 mRNA antagonist is selected from the group consisting of:
[0360] 5'T s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T 3' (SEQ ID NO 13, #13, 1)
[0361] 5’A s t s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T 3’(SEQ ID NO 15,#15,3)
[0362] 5’C s T s T s C s t s t s c s t s a s t s c s t s a s m c s g s c s A s T 3’(SEQ ID NO 17,#17),
[0363] 5’T s A s C s T s t s t s a s a s t s a s g s c s T s C s A s A 3’(SEQ ID NO 18,#18);and
[0364] 5’T s T s C s t s a s t s c s t s a s m c s gs c s a s T s T s G 3' (SEQ ID NO 19, #19),
[0365] The capital letters represent β-D-oxy LNA nucleoside units, the lowercase letters represent DNA nucleoside units, and the subscript s represents the phosphorothioate internucleoside linkage. m c represents 5-methylcytosine nucleoside, and all LNA cytosines are 5-methylcytosine; or a pharmaceutically acceptable salt thereof.
[0366] 18. A method for treating a subject having or at risk of developing macular degeneration, the method comprising performing the method according to any one of embodiments 1-17, and administering to the subject an effective amount of an HTRA1 mRNA antagonist.
[0367] 19. The method according to any one of embodiments 1-17, wherein the HTRA1 mRNA antagonist is for administration via intravitreal administration.
[0368] 20. Use of HTRA1 antibodies as companion diagnostics for HTRA1 RNA antagonist therapy.
[0369] 21. Use of an HTRA1 antibody as a biomarker for therapeutic efficacy of an HTRA1 RNA antagonist, eg an HTRA1 mRNA antagonist, such as an HTRA1 mRNA antagonist according to any one of the preceding embodiments.
[0370] 22. Use of an HTRA1 antibody for detecting HTRA1 levels in a sample of aqueous or vitreous humor obtained from a subject who is undergoing treatment with, or being evaluated for suitability for treatment with, an HTRA1 mRNA antagonist, such as an HTRA1 mRNA antagonist according to any one of the preceding embodiments.
[0371] 22. Use of a biomarker for determining a subject's likely response to a therapeutic agent comprising an HTRA1 mRNA antagonist, such as according to any one of the preceding embodiments, wherein the biomarker comprises an elevated level of HTRA1 in a biological sample obtained from the aqueous humor or vitreous humor from the subject compared to the level of HTRA1 obtained from a reference sample from a healthy subject. Example
[0372] Oligonucleotide synthesis
[0373] Oligonucleotide synthesis is well known in the art. The following protocols may be used. The oligonucleotides of the present invention may be prepared by methods with slight variations in the apparatus, support and concentration used.
[0374] Oligonucleotides were synthesized on a uridine universal support using the phosphoramidite method on an Oligomaker 48 at a 1 μmol scale. At the end of the synthesis, the oligonucleotides were cleaved from the solid support using ammonia at 60°C for 5-16 hours. Oligonucleotides were purified by reverse phase HPLC (RP-HPLC) or by solid phase extraction and characterized by UPLC, and the molecular weight was further confirmed by ESI-MS.
[0375] Extension of oligonucleotides:
[0376] Coupling of β-cyanoethylphosphoramidites (DNA-A(Bz), DNA-G(ibu), DNA-C(Bz), DNA-T, LNA-5-methyl-C(Bz), LNA-A(Bz), LNA-G(dmf), LNA-T) was performed by using a 0.1 M solution of the 5′-O-DMT protected amidite in acetonitrile and a solution of DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M) as an activator. For the final cycle, a phosphoramidite with the desired modification (e.g., a C6 linker for attaching a conjugate group or a conjugate group like this) can be used. Thiolation for the introduction of phosphorothioate linkages is performed by using xanthanehydride (0.01 M in acetonitrile / pyridine 9:1). Phosphodiester linkages can be introduced using 0.02 M iodine in THF / pyridine / water 7:2:1. The remaining reagents are those commonly used for oligonucleotide synthesis.
[0377] For conjugation after solid phase synthesis, a commercially available C6 amino linker phosphoramidite can be used in the last cycle of solid phase synthesis and after deprotection and cleavage from the solid support, the amino-linked deprotected oligonucleotide is isolated. The conjugate is introduced by activating the functional group using standard synthetic methods.
[0378] Purification by RP-HPLC:
[0379] The crude compound was purified by preparative RP-HPLC on a Phenomenex Jupiter C18 10μ 150x10mm column. 0.1M ammonium acetate pH 8 and acetonitrile were used as buffers at a flow rate of 5 mL / min. The collected fractions were lyophilized to give the purified compound, usually as a white solid.
[0380] Example 1. In vivo pharmacokinetic and pharmacodynamic (PK / PD) study in cynomolgus monkeys (non-human primates, NHP), treated for 21 days, intravitreal (IVT) injection, single dose.
[0381] For one selected HTRA1 LNA oligonucleotide, 15.3, targeting a "hotspot" in the human HTRA1 pre-mRNA (between positions 33042-33064), knockdown was observed at both the mRNA level in the retina and the protein level in both the retina and vitreous (see Figure 6)
[0382] animal
[0383] All experiments were performed in Cynomolgus monkeys (Macaca fascicularis).
[0384] Compounds and dosing schedule
[0385] Buprenorphine analgesia was administered before and two days after test compound injection. Animals were anesthetized with intramuscular injections of ketamine and xylazine. Test articles and negative controls (PBS) were administered intravitreally (50 μL per administration) to both eyes of anesthetized animals on study day 1 after topical administration of tetracaine anesthetic.
[0386] Euthanasia
[0387] At the end of the life stage (day 22), all monkeys were euthanized by an intraperitoneal overdose of pentobarbital.
[0388] Measurement of oligonucleotide content and quantification of Htra1 RNA expression by qPCR
[0389] Immediately after euthanasia, eye tissues were quickly and carefully sliced on ice and stored at -80°C until shipment. Retinal samples were lysed in 700 μL MagNa Pure 96LC RNA isolation tissue buffer and homogenized 2x1,5 min by adding 1 stainless steel bead per 2 ml tube using a precellys evolution homogenizer, then incubated at room temperature for 30 minutes. The samples were centrifuged at 13000 rpm for 5 min. Half was set aside for bioanalysis and the other half was directly subjected to RNA extraction.
[0390] For bioanalysis, samples were diluted 10 to 50 times and oligonucleotide content was measured by hybridization ELISA. Biotinylated LNA capture probes and digoxigenin-conjugated LNA detection probes (both 35 nM in 5xSSCT, each complementary to one end of the LNA oligonucleotide to be detected) were mixed with the diluted homogenate or relevant standards, incubated at room temperature for 30 minutes and then added to streptavidin-coated ELISA plates (Nunc catalog number 436014).
[0391] The plate was incubated at room temperature for 1 hour and washed in 2×SSCT (300 mM sodium chloride, 30 mM sodium citrate and 0.05% v / v Tween-20, pH 7.0). The captured LNA duplex was detected using an anti-DIG antibody conjugated with alkaline phosphatase (Roche Applied Science cat. No. 11093274910) and an alkaline phosphatase substrate system (Blue Phos substrate, KPL product code 50-88-00). The amount of oligomeric complexes was measured on a Biotek reader as absorbance at 615 nm.
[0392] For RNA extraction, the Cellular RNA High Capacity Kit (05467535001, Roche) was used on the MagNA Pure 96 system with the following procedure: Tissue FF Standard LV3.1 was prepared according to the manufacturer's instructions, including DNAse treatment. RNA quality control and concentration were measured with Eon Reader (Biotek). RNA concentration was standardized between samples, followed by cDNA synthesis and qPCR in a one-step reaction using qScript XLT one-step RT-qPCR ToughMix Low ROX, 95134-100 (Quanta Biosciences). The following TaqMan primer assays were used in the single-stranded reactions: Htra1, Mf01016150_, Mf01016152_m1 and Rh02799527_m1 and housekeeping genes, ARFGAP2, Mf01058488_g1 and Rh01058485_m1, and ARL1, Mf02795431_m1 from Life Technologies. qPCR analysis was performed on a ViiA7 machine (Life Technologies). Eyes / group: n=3 eyes. Each eye was considered an individual sample. The relative Htra1 mRNA expression levels in the table are shown as % of the control (PBS).
[0393] Histology
[0394] The eyeballs were removed and fixed in 10% neutral buffered formalin for 24 h, trimmed and embedded in paraffin.
[0395] For ISH analysis, formalin-fixed, paraffin-embedded retinal tissue sections at a thickness of 4 μm were processed using the fully automated Ventana Dicovery ULTRA staining module (program: mRNADiscovery Ultra Red 4.0-v0.00.0152) using RNAscope 2.5 VS Probe-mMu-HTRA1, REF486979, Advanced Cell Diagnostics, Inc. The chromogen used was Fastred, Hematoxylin II counterstain.
[0396] Quantification of HTRA1 protein using a plate-based immunoprecipitation mass spectrometry (IP-MS) approach
[0397] Sample preparation, retina
[0398] The retina was homogenized (5500, 15 s, 2 cycles) in 4 volumes (w / v) of RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, Millipore) with protease inhibitors (complete EDTA-free, Roche) using a Precellys 24. The homogenate was centrifuged (13,000 rpm, 3 min) and the protein content of the supernatant was determined (Pierce BCA protein assay).
[0399] Sample preparation, vitreous
[0400] The vitreous fluid (300 μl) was diluted with 5×RIPA buffer (final concentration: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) with protease inhibitors (complete EDTA-free, Roche) and homogenized using a Precellys 25 (5500, 15 s, 2 cycles). The homogenate was centrifuged (13,000 rpm, 3 min) and the protein content of the supernatant was determined (Pierce BCA protein assay)
[0401] Plate-based HTRA1 immunoprecipitation and trypsin digestion
[0402] 96-well plates (Nunc MaxiSorp) were coated with anti-HTRA1 mouse monoclonal antibody (R&D MAB2916, 500ng / well in 50μl PBS) and incubated overnight at 4°C. The plates were washed twice with PBS (200μl) and blocked with 3% (w / v) BSA in PBS at 20°C for 30 minutes, followed by two PBS washes. Samples (75μg retina, 100μg vitreous in 50μl PBS) were randomized and added to the plates, followed by incubation overnight at 4°C on a shaker (150rpm). The plates were then washed twice with PBS and once with water. 10mM DTT in 50mM TEAB (30μl) was then added to each well, followed by incubation at 20°C for 1h to reduce cysteine thiols. Then 150 mM iodoacetamide in 50 mM TEAB (5 μl) was added to each well, followed by incubation at 20°C for 30 minutes in the dark to block cysteine thiol groups. 10 μl of digestion solution (final concentration: 1.24 ng / μl trypsin, 20 fmol / μl BSA peptide, 26 fmol / μl isotope-labeled HTRA1 peptide, 1 fmol / μl iRT peptide, Biognosys) was added to each well, followed by incubation overnight at 20°C.
[0403] HTRA1 peptide quantification by targeted mass spectrometry (selected reaction monitoring, SRM)
[0404] Mass spectrometry analysis was performed on an UltimateRSLCnano LC coupled to a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Scientific). Samples (20 μL) were injected directly from a 96-well plate for IP and loaded onto an Acclaim Pepmap 100 trap column (100 μm x 2 cm, C18, 5 μm, The peptides were then analyzed on a PepMap Easy-SPRAY analytical column (75 μm x 15 cm, 3 μm, The separation was performed on a ThermoScientific using the following gradient at a flow rate of 250 nL / min: 6 min, 98% buffer A (2% ACN, 0.1% formic acid), 2% buffer B (ACN + 0.1% formic acid); 36 min, 30% buffer B; 41 min, 60% buffer B; 43 min, 80% buffer B; 49 min, 80% buffer B; 50 min, 2% buffer B. The TSQ Quantiva was operated in SRM mode with the following parameters: cycle time, 1.5 s; spray voltage, 1800 V; collision gas pressure, 2 mTorr; Q1 and Q3 resolution, 0.7 FWHM; ion transfer tube temperature 300°C. SRM transitions were obtained for the HTRA1 peptide "LHRPPVIVLQR" and the isotopically labeled (L-[U-13C, U-15N]R) synthetic form (which was used as an internal standard). Data analysis was performed using Skyline version 3.6.
[0405] Example 2 Pharmacokinetic and pharmacodynamic study in cynomolgus monkeys, treated for 21 days, intravitreal (IVT) injection, single dose.
[0406] With three HTRA1 LNA oligonucleotides targeting a "hotspot" in the human HTRA1 pre-mRNA (between positions 53113-53384), knockdown was observed at both the mRNA level in the retina and the protein level in both the retina and vitreous.
[0407] animal
[0408] All experiments were performed in Cynomolgus monkeys (Macaca fascicularis).
[0409] Four animals were included in each study, for a total of 20 animals.
[0410] Compounds and dosing schedule
[0411] Buprenorphine analgesia was administered before and two days after test compound injection. Animals were anesthetized with intramuscular injections of ketamine and xylazine. Test articles and negative controls (PBS) were administered intravitreally (50 μL per administration) to both eyes of anesthetized animals on study day 1 after topical administration of tetracaine anesthetic.
[0412] Euthanasia
[0413] At the end of the life stage (day 22), all monkeys were euthanized by an intraperitoneal overdose of pentobarbital.
[0414] Measurement of oligonucleotide content and quantification of Htra1 RNA expression by qPCR
[0415] Immediately after euthanasia, eye tissues were quickly and carefully sliced on ice and stored at -80°C until shipment. Retinal samples were lysed in 700 μL MagNa Pure 96 LC RNA isolation tissue buffer and homogenized 2x1,5 min by adding 1 stainless steel bead per 2 ml tube using a precellys evolution homogenizer, then incubated at room temperature for 30 minutes. The samples were centrifuged at 13000 rpm for 5 min. Half was set aside for bioanalysis and the other half was directly subjected to RNA extraction.
[0416] For bioanalysis, samples were diluted 10 to 50 times and oligonucleotide content was measured by hybridization ELISA. Biotinylated LNA capture probes and digoxigenin-conjugated LNA detection probes (both 35 nM in 5xSSCT, each complementary to one end of the LNA oligonucleotide to be detected) were mixed with the diluted homogenate or relevant standards, incubated at room temperature for 30 minutes and then added to streptavidin-coated ELISA plates (Nunc catalog number 436014).
[0417] The plate was incubated at room temperature for 1 hour and washed in 2×SSCT (300 mM sodium chloride, 30 mM sodium citrate and 0.05% v / v Tween-20, pH 7.0). The captured LNA duplex was detected using an anti-DIG antibody conjugated with alkaline phosphatase (Roche Applied Science cat. No. 11093274910) and an alkaline phosphatase substrate system (Blue Phos substrate, KPL product code 50-88-00). The amount of oligomeric complexes was measured on a Biotek reader as absorbance at 615 nm.
[0418] For RNA extraction, the Cellular RNA High Capacity Kit (05467535001, Roche) was used on the MagNA Pure 96 system with the following procedure: Tissue FF Standard LV3.1 was prepared according to the manufacturer's instructions, including DNAse treatment. RNA quality control and concentration were measured with Eon Reader (Biotek). RNA concentration was standardized between samples, followed by eDNA synthesis and qPCR in a one-step reaction using qScript XLT one-step RT-qPCR ToughMix Low ROX, 95134-100 (Quanta Biosciences). The following TaqMan primer assays were used in the single-stranded reactions: Htra1, Mf01016150_, Mf01016152_m1 and Rh02799527_m1 and housekeeping genes, ARFGAP2, Mf01058488_g1 and Rh01058485_m1, and ARL1, Mf02795431_m1 from Life Technologies. qPCR analysis was performed on a ViiA7 machine (Life Technologies). Eyes / group: n=3 eyes. Each eye was considered an individual sample. The relative Htra1 mRNA expression levels in the table are shown as % of the control (PBS).
[0419] Histology
[0420] The eyeballs were removed and fixed in 10% neutral buffered formalin for 24 h, trimmed and embedded in paraffin.
[0421] For ISH analysis, formalin-fixed, paraffin-embedded macaque retinal tissue sections at a thickness of 4 μm were processed using the fully automated Ventana Dicovery ULTRA staining module (program: mRNADiscovery Ultra Red 4.0-v0.00.0152) with RNAscope 2.5 VS Probe-mMu-HTRA1, REF486979, Advanced Cell Diagnostics, Inc. The chromogen used was Fastred, hematoxylin II counterstain.
[0422] Quantification of HTRA1 protein using a plate-based immunoprecipitation mass spectrometry (IP-MS) approach
[0423] Sample preparation, retina
[0424] The retina was homogenized in 4 volumes (w / v) of RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA, Millipore) with protease inhibitors (complete EDTA-free, Roche) using a Precellys 24 (5500, 15 s, 2 cycles). The homogenate was centrifuged (13,000 rpm, 3 min) and the protein content of the supernatant was determined (Pierce BCA protein assay)
[0425] Sample preparation, vitreous
[0426] The vitreous fluid (300 μl) was diluted with 5× RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) with protease inhibitors (complete EDTA-free, Roche) and homogenized using a Precellys 25 (5500, 15 s, 2 cycles). The homogenate was centrifuged (13,000 rpm, 3 min) and the protein content of the supernatant was determined (Pierce BCA protein assay)
[0427] Plate-based HTRA1 immunoprecipitation and trypsin digestion
[0428] 96-well plates (Nunc MaxiSorp) were coated with anti-HTRA1 mouse monoclonal antibody (R&D MAB2916, 500ng / well in 50μl PBS) and incubated overnight at 4°C. The plates were washed twice with PBS (200μl) and blocked with 3% (w / v) BSA in PBS at 20°C for 30 minutes, followed by two PBS washes. Samples (75μg retina, 100μg vitreous in 50μl PBS) were randomized and added to the plates, followed by incubation overnight at 4°C on a shaker (150rpm). The plates were then washed twice with PBS and once with water. 10mM DTT in 50mM TEAB (30μl) was then added to each well, followed by incubation at 20°C for 1h to reduce cysteine thiols. Then 150 mM iodoacetamide in 50 mM TEAB (5 μl) was added to each well, followed by incubation at 20°C for 30 minutes in the dark to block cysteine thiol groups. 10 μl of digestion solution (final concentration: 1.24 ng / μl trypsin, 20 fmol / μl BSA peptide, 26 fmol / μl isotope-labeled HTRA1 peptide, 1 fmol / μl iRT peptide, Biognosys) was added to each well, followed by incubation overnight at 20°C.
[0429] HTRA1 peptide quantification by targeted mass spectrometry (selected reaction monitoring, SRM)
[0430] Mass spectrometry analysis was performed on an UltimateRSLCnano LC coupled to a TSQ Quantiva triple quadrupole mass spectrometer (Thermo Scientific). Samples (20 μL) were injected directly from a 96-well plate for IP and loaded onto an Acclaim Pepmap 100 trap column (100 μm x 2 cm, C18, 5 μm, The peptides were then analyzed on a PepMap Easy-SPRAY analytical column (75 μm x 15 cm, 3 μm, ThermoScientific.) using the following gradient at a flow rate of 250 nL / min: 6 min, 98% buffer A (2% ACN, 0.1% formic acid), 2% buffer B (ACN + 0.1% formic acid); 36 min, 30% buffer B; 41 min, 60% buffer B; 43 min, 80% buffer B; 49 min, 80% buffer B; 50 min, 2% buffer B. The TSQ Quantiva was operated in SRM mode with the following parameters: cycle time, 1.5 s; spray voltage, 1800 V; collision gas pressure, 2 mTorr; Q1 and Q3 resolution, 0.7 FWHM; ion transfer tube temperature 300°C. SRM transitions were obtained for the HTRA1 peptide "LHRPPVIVLQR" and the isotopically labeled (L-[U-13C, U-15N]R) synthetic form (which was used as an internal standard).
[0431] Data analysis was performed using Skyline version 3.6.
[0432] Western blotting
[0433] The sliced retinal samples in 0.5 Precellyses tubes (CK14_0.5 ml, Bertin Technologies) were lysed and homogenized in RIPA lysis buffer (20-188, Milipore) with protease inhibitors (Complete EDTA-free Protease-Inhibitor mini, 11 836170 001, Roche).
[0434] The vitreous samples were added to 0.5 Precellyses tubes (CK14_0.5 ml, Bertin Technologies) and lysed and homogenized in 1 / 4x RIPA lysis buffer (20-188, Milipore) with protease inhibitors (Complete EDTA-free Protease-Inhibitor mini, 11 836170 001, Roche).
[0435] Samples (20 μg protein for retina, 40 μg protein for vitreous) were analyzed on 4-15% gradient gels (#567-8084 Bio-Rad) under reducing conditions and transferred to nitrocellulose (#170-4159 Bio-Rad) using a Trans-Blot Turbo apparatus from Bio-Rad.
[0436] Primary antibodies: Rabbit anti-human HTRA1 (SF1) was a kind gift from Sascha Fauser (University of Cologne), mouse anti-human Gapdh (#98795 Sigma-Aldrich). Secondary antibodies: Goat anti-rabbit 800CW and goat anti-mouse 680RD were from Li-Cor
[0437] Blots were imaged and analyzed on an Odyssee CLX from Li-Cor.
[0438] Example 3 - In vivo evaluation in cynomolgus monkeys: HTRA1 protein determination in aqueous humor and comparison with HTRA1 mRNA and protein inhibition in the retina.
[0439] Experimental Method: See Example 2. Collect aqueous humor samples and prepare the samples according to the vitreous humor samples in Example 2. Cynomolgus monkey aqueous humor samples (AH) were analyzed by size-based assay on the Analytical Methodology: Capillary Electrophoresis System (Peggy Sue TM , Proteinsimple).
[0440] Samples were thawed on ice and used undiluted. For quantification, recombinant HTRA1-S328A mutant (Origene #TP700208) was prepared as described by the supplier.
[0441] The primary rabbit anti-human HTRA antibody SF1 was provided by Prof. Dr. Sascha Fauser and used at a dilution of 1: 300. All other reagents were from Proteinsimple.
[0442] Samples were processed in technical triplicate using a 12-230 kDa separation module and calibration curves in duplicate. Areas under peaks were calculated and analyzed using Xlfit (IDBS Software).
[0443] result
[0444]
[0445] Fig. 9A Shown is a visualization of HTRA1 protein levels in the aqueous humor of monkeys administered compounds #15, 3, and #17, with samples collected at 3, 8, 15, and 22 days post-injection. Fig. 9B A calibration curve for calculating HTRA1 protein levels is provided. Fig. 9C Calculated HTRA1 levels in aqueous humor from individual animals are presented plotted against time after injection.
[0446] Fig.10 A direct correlation between HTRA1 protein levels in the aqueous humor and HTRA1 mRNA levels in the retina is shown. Therefore, aqueous humor HTRA1 protein levels can be used as a biomarker for HTRA1 retinal mRNA levels or HTRA1 retinal mRNA inhibition.
[0447] Fig.11 It shows that there is also a correlation between HTRA1 protein levels in the retina and HTRA1 protein levels in the aqueous humor, although in this experiment, the correlation is not as strong as the correlation between HTRA1 mRNA inhibition in the retina and HTRA1 protein levels in the aqueous humor, indicating that aqueous humor HTRA1 protein levels are particularly suitable as a biomarker for HTRA1 mRNA antagonists.
[0448] Example 4: In vivo pharmacokinetic and pharmacodynamic study in cynomolgus monkeys, 36 days of treatment, intravitreal (IVT) injection, single dose.
[0449] The dynamics of HTRA1 protein in the aqueous humor of animals exposed to HTRA1 LNAs were investigated over 36 days, and the amount of residual HTRA1 protein was examined in different ocular tissue compartments (vitreous, neural retina, retinal pigment epithelium (RPE), and choroid) after necropsy. HTRA1 mRNA inhibition was assessed in terminal samples.
[0450] animal
[0451] All experiments were performed on male cynomolgus monkeys (Macaca fascicularis) at the facilities of Charles Rivers Laboratories Montreal ULC in Sennville, Canada.
[0452] Compounds and dosing schedule
[0453] Topical antibiotics (tobramycin) were applied to both eyes twice a day before and twice a day after each injection. Prior to dosing, fasted animals received an intramuscular injection of a sedative mixture of ketamine (5 mg / kg) and dexmetedomidine (0.01 mg / kg) followed by mixed isoflurane / oxygen via mask. A local anesthetic (0.5% proparacaine) was instilled slowly into each eye prior to bilateral intravitreal injections of 100 μg of test article or vehicle (phosphate-buffered saline) in 50 μl. Mydriatic drops (1% tropicamide) were instilled into each eye as needed. After completion of the dosing procedure, animals received an intramuscular injection of 0.1 mg / kg of atipamezole, a reversal agent for dexmetedomidine
[0454] On day 0 of the procedure, 4 animals were injected bilaterally with 100 μg of HTRA1 LNA#18 in 50 μl, and 4 animals were injected with the same volume of vehicle.
[0455] Aqueous humor sampling
[0456] Animals were divided into two groups, each group including two control and two treated monkeys. Aqueous humor samples were collected at baseline (all animals); Day 3 and Day 18 (1 group); Day 11, Day 25, (2 groups) Day 32 (all animals) and Day 36 after euthanasia. Animals were anesthetized according to the same procedure as compound application, and 30-40 μl of aqueous humor was sampled after pupil dilation and stored frozen at -80°C.
[0457] Euthanasia
[0458] On day 36, fasted animals were anesthetized with ketamine and isoflurane, the aorta and vena cava were clamped, and the upper body was transcardially perfused with phosphate-buffered saline. The flushed eyeballs were removed and cleaned from adherent tissues, and 200 μl of aqueous humor were sampled. The left eye was further processed for RNA preparation and the right eye for protein analysis. HTRA1 protein in aqueous humor was measured from left and right eyes at necropsy.
[0459] Sample processing for HTRA1 protein analysis
[0460] For final collection, up to 0.2 ml of aqueous humor was harvested using an ultrafine insulin syringe with a 30G, 1 / 2" needle, and the globe was cleaned from adherent muscle and opened frontally through a circumferential incision 3 mm posterior to the limbus. The vitreous was removed, homogenized by forcing the tissue (3 passes) through a 3cc needleless syringe, centrifuged (3 min 16,000 x g, 4°C) and stored frozen. The neural retina was carefully peeled off from the underlying RPE and snap-frozen on dry ice. The opened cup was then kept front-up and lysed with 1% paraformaldehyde containing protease inhibitors (cOmplete TM 1ml RIPA buffer (Millipore, 50mM Tris-HCl, pH7.4, 150mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1mM EDTA) of EDTA-free protease inhibitor cocktail, mini, Roche, 1 tablet / 10ml) was filled and shaken (200rpm) for 5 minutes on a rotating platform. The resulting RPE lysate was cleaned by centrifugation (3 minutes, 16,000xg at 4°C) and stored frozen. The remaining posterior cup was rinsed off with phosphate buffered saline, four incisions were made to allow the tissue to lie flat, and Bruch's membrane and adherent choroid were peeled off. Choroid was homogenized 3 times in 4ml of tissue RIPA buffer containing protease inhibitors per gram using a Geno grinder (1500rpm, 2 minutes), cooled on ice during the period. Debris was removed by centrifugation, and the extract was stored (3 minutes at 4°C, 16,000xg).
[0461] The vitreous humor was diluted with 5x RIPA buffer (final concentration: 50 mM TrisHCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) with protease inhibitors (complete EDTA-free, Roche) and homogenized using a Precellys 25 (5500 rpm, 15 s, 2 cycles). The homogenate was centrifuged (16,000 x g, 3 min). The protein content of neural retinal and choroidal extracts was measured using the bicmchoninic acid method and reagents from Pierce (Rockford USA) with serum albumin as standard.
[0462] Sample processing for RNA preparation
[0463] For RNA preparation, the initial dissection steps are similar to those for protein.
[0464] The peeled retina was transferred to a homogenization container and 10 μl / mg tissue homogenization buffer (Maxwell RNA isolation kit, Promega) was added. The material was processed in a Geno grinder at 1500 rpm for three 2-minute cycles. The resulting lysate was stored at -80°C until further processing.
[0465] After removal of the neural retina, the open cup was filled with RNA Protect Cell Reagent (Qiagen) and shaken on a rotating platform (400 rpm) at 4°C. The resulting RPE cell suspension was collected after 10 minutes, centrifuged at 700g for 5 minutes and lysed in 200 μl Maxwell homogenization buffer. The lysate was stored at -80°C until further processing.
[0466] Fresh RNA protection solution is added to the eye cup, and then shaken for 10 minutes to remove remaining RPE cells and discard. Four incisions are made to allow the tissue to lay flat, and Bruch's membrane and the choroid of adhesion are peeled off, and frozen storage is until further processing. For homogenization, the frozen choroid is added to Promega homogenization buffer (10 μl / mg tissue) without thawing, and 3 2-minute cycles are processed at 20 Hz in tissue lysate II (Retsch).
[0467] RNA was purified from lysates using a Maxwell RNA isolation robot and corresponding reagents (Promega) according to the supplier's instructions.
[0468] RNA quality was assessed and quantity was measured by capillary electrophoresis on an Expefion apparatus (BioRad).
[0469] Quantification of HTRA1 mRNA using RNA sequencing
[0470] Using TruSeq TM 400 ng of total RNA was used to prepare mRNA sequencing libraries using the Illumina 20020594 mRNA library preparation kit. The libraries were sequenced on an Illumina HiSeq 4000 sequencer (2x50 bp). https: / / support.illumina.com / downloads.html) FASTQ file converter bcl2fastq v2.17.1.14 performs base calling (Base calling). In order to estimate gene expression levels, the paired-end RNASeq readings are mapped to the Macaca fascicularis genome (macFas5 from WashU) (Dobin et al. 2013) using STAR aligner version 2.5.2a using default mapping parameters. The number (count) of the mapped readings of all RefSeq transcript variants of a gene is combined into a single value by using SAMTOOLS software (Li et al. 2009), and is standardized to rpkms (the number of mapped readings of every kilobase transcript per million sequencing reads, Mortazavi et al. 2008).
[0471] Quantification of HTRA1 protein using a capillary electrophoresis-based method
[0472] As described by the supplier, proteins from different eye compartments were analyzed by capillary electrophoresis using a 12-230 kDa separation matrix on a Peggy Sue apparatus (Protein Simple, San Jose, California, USA). Human recombinant 6His-tagged HTRA1 S328A (RD Biotech, France) samples (62.5-.0.12 ng / ml) were analyzed in parallel for quantification. HTRA1 protein was detected by using rabbit anti-human HTRA1 antiserum SF1 (dilution 1:300) provided by Professor Dr. Sascha Fauser. Cynomolgus monkey RPE lysate containing 5.5 ng / ml HTRA1s was used to evaluate the repeatability of the assay.
[0473] Since matrix effects were ruled out by preliminary experiments (not shown), samples were analyzed at the highest possible concentration to enable optimal quantification of HTRA1 inhibition. Aqueous humor samples were used undiluted; while clarified homogenized vitreous samples were diluted 80% in RIPA buffer containing protease inhibitors. The concentration of neural retina, RPE, and choroidal lysates was adjusted to 0.5 mg total protein / ml.
[0474] Throughout the study, the intra-assay variation was 9.1% and the inter-assay variation was 21%. To improve comparability, all samples from each tissue were analyzed in a single run, except for aqueous humor samples collected at different time points analyzed in a run different from the final sample.
[0475] Result 1: HTRA1 protein inhibition in different tissue compartments at necropsy 32 days after LNA application:
[0476] The highest HTRA1 concentration was found in choroidal lysates (PBS group: 28 ng / mg total protein sd=2.2), with LNA treatment causing only a slight inhibition in this anatomical region (16% decrease in LNA group: 24 ng / mg total protein sd=3.5).
[0477] The lowest HTRA1 concentration measured was in RPE lysate (PBS group: 5.2 ng / mg total protein sd=0.4), with a significant intervention effect of 1 (55% decrease, LNA group: 2.4 ng / mg total protein sd=0.2).
[0478] The greatest effects of the intervention were observed in the neural retina, vitreous humor, and aqueous humor (AH), with mean HTRA1 levels being 76; 84; and 74% lower than vehicle-treated animals, respectively. Fig. 12A Group average inhibition in different compartments is shown in .
[0479] Despite the scatter in HTRA1 values identified in the control group, HTRA1 concentrations measured in the vitreous, retina, and RPE were generally consistent with levels measured in the aqueous humor; demonstrating potential validity as a target engagement biomarker. The correlation between tissue HTRA1 levels and aqueous humor levels is shown in Fig. 12B
[0480] Results 2: Dynamics of HTRA1 protein concentration in aqueous humor
[0481] Due to insufficient sample availability, one baseline sample could not be measured and the animal (vehicle treated, Group 1) was excluded from the current analysis.
[0482] Baseline HTRA1 protein concentrations in aqueous humor were heterogeneous (4.32 ng / ml standard deviation (sd) 0.98 ng / ml) with higher values in the treated groups. (Active treatment 3.65 ng / ml sd 0.18 ng / ml, vehicle 5.23 ng / ml sd 0.82 ng / ml). There was a trend towards an increase in HTRA1 concentrations in both groups on day 3 after IVT (active treatment: n=2, +51% and +54%; vehicle n=1, +42%). Therefore, the effect of the intervention was analyzed after normalization to individual baseline values and a time-matched vehicle group. The treatment had no effect on day 3, but aqueous humor HTRA1 concentrations were reduced (52%) from day 11 onwards, with an effect reaching 66% inhibition on day 36. Data are shown in Figure 2. Fig.13 shown.
[0483] Result 3: HTRA1 mRNA suppression in different tissue compartments at necropsy 32 days after LNA application:
[0484] HTRA1 mRNA levels were measured by RNA sequencing in the retina, RPE, and choroid dissected from the left eyes of eight animals (4 animals in the vehicle group and 4 animals in the LNA-treated group). An average of 129,876,690 reads were generated per sample and an average of 122,038,760 mapped reads were generated per sample. One retinal sample was excluded from the vehicle and LNA groups and one RPE sample was excluded from the vehicle group due to failure to pass quality control measurements. In the remaining samples, levels of HTRA1 mRNA in the retina were significantly and robustly reduced after LNA treatment (80% reduction in the LNA group compared to the vehicle group). A slightly lower (60%) but significant reduction was observed in the RPE after LNA treatment. No significant reduction was seen in the choroid (see Figure 5). Fig.14 ).
[0485] in conclusion
[0486] A single intravitreal injection of 100 μg HTRA1 LNA in cynomolgus monkeys resulted in an 80% reduction in HTRA1 mRNA expression in the neural retina and a 60% reduction in retinal pigment epithelial cells 36 days after exposure. Correspondingly, HTRA1 protein was reduced by 76% and 55% in the neural retina and RPE, respectively, indicating the sustained drug activity and wide distribution and efficacy of the drug in the different eye compartments studied. As expected, the choroid is only minimally reached by oligonucleotides due to the blood-retinal barrier. Therefore, no significant reduction in HTRA1 mRNA was observed in this tissue. Importantly, these data show that there is a significant and long-term impact on the RPE layer, which plays a pivotal role in the pathogenesis of AMD. The strong correlation between HTRA1 inhibition in mRNA and protein levels indicates that local HTRA1 synthesis is the main source of the ocular protein pool, and the proportion of blood-derived HTRA1 is negligible.
[0487] HTRA1 protein levels in the essentially acellular vitreous and aqueous humor were reduced to a similar extent as in the neural retina (r84% and 74%, respectively), indicating that protein concentrations in these biological fluids can be used to assess the effectiveness of retro-ocular interventions. Decreases in the aqueous humor could not be detected before day 11, suggesting a delayed onset of action and / or low HTRA1 protein turnover in this compartment.
[0488] References
[0489] Dobin et al. 2013, Bioinformatics 29: "STAR: ultrafast universal RNA-seqaligner"
[0490] Li et al. 2009, Bioinformatics 25: "The Sequence Alignment / Map format and SAMtools"
[0491] Mortazavi et al. 2008. Nature Methods 5: "Mapping and quantifying mammalian transcriptomes by RNA-Seq".
Claims
1. A method for determining the suitability of a subject for treatment with an HTRA1 mRNA antagonist, the method comprising the steps of: i) determining the level of HTRA1 in a sample of aqueous humor or vitreous humor obtained from the subject ii) comparing the level of HTRA1 obtained in step i) with one or more reference samples or reference values; to determine whether the subject is likely or suitable for treatment with an HTRA1 mRNA antagonist, wherein the subject suffers from or is at risk of developing an ocular disorder such as macular degeneration. 2 . The method of claim 1 , wherein the level of HTRA1 in the sample of aqueous humor or vitreous humor is determined by quantifying the level of HTRA1 protein in the sample.
3. The method of claim 2, wherein the level of HTRA1 protein is determined using an immunoassay, such as using an HTRA1-specific antibody. The method of claim 3 , wherein the level of HTRA1 protein is determined using mass spectrometry.
5. The method according to any one of claims 1-4, wherein at least one of the reference sample or reference value is obtained from a control subject with macular degeneration.
6. The method according to any one of claims 1-5, wherein at least one of the reference sample or reference value is obtained from a control subject not suffering from macular degeneration.
7. The method according to any one of claims 1 to 6, wherein at least one of the reference samples is a value previously obtained from the same subject whose suitability for treatment is being assessed.
8. The method according to any one of claims 1 to 7, wherein the reference value is derived from a data set that models the correlation between the HTRA1 concentration in the retina and the HTRA1 concentration in the aqueous humor or vitreous humor.
9. The method according to any one of claims 1-8, wherein the HTRA1 mRNA antagonist is selected from the group consisting of: antisense oligonucleotides targeting HTRA1 mRNA or pre-mRNA, siRNA targeting HTRA1 mRNA, ribozymes targeting HTRA1 mRNA or pre-mRNA.
10. The method according to any one of claims 1-9, wherein the method is used to determine whether the subject has enhanced HTRA1 expression in the retina.
11. according to the method described in any one of claims 1-10, wherein the experimenter suffers from or is at risk of developing an ocular condition, the ocular condition being selected from the group consisting of: macular degenerative diseases, such as age-related macular degeneration (AMD), including wet (exudative) AMD (including early, intermediate and late wet AMD) and dry (non-exudative) AMD (including early, intermediate and late dry AMD (e.g. geographic atrophy (GA)); diabetic retinopathy (DR) and other ischemia-related retinopathies; endophthalmitis; uveitis; choroidal neovascularization (CNV); retinopathy of prematurity (ROP); polypoidal choroidal vasculopathy (PCV); diabetic macular edema; pathological myopia; von Hippel-Lindau disease; ocular histoplasmosis; central retinal vein occlusion (CRVO); corneal neovascularization and retinal neovascularization.
12. according to the method described in any one of claim 1-11, wherein the experimenter suffers from age-related macular degeneration (AMD) or is in the risk of age-related macular degeneration (AMD) occurring, such as the AMD is selected from the group consisting of the following: wet (exudative) AMD (comprising early stage, mid-term and late stage wet AMD), dry (non-exudative) AMD (comprising early stage, mid-term and late stage dry AMD (for example, geographic atrophy (GA)).
13. The method according to any one of claims 1 to 12, wherein the method is used to determine a suitable dosage regimen for administering an HTRA1 mRNA antagonist.
14. The method according to any one of claims 1 to 13, wherein the HTRA1 mRNA antagonist is an oligonucleotide comprising a contiguous nucleotide region of 10 to 30 nucleotides that is fully complementary to an HTRA1 target nucleic acid sequence such as SEQ ID NO 1 or SEQ ID NO 2.
15. The method according to any one of claims 1-14, wherein the HTRA1 mRNA antagonist is or comprises an oligonucleotide comprising a contiguous nucleotide sequence of at least 12 nucleotides in length that is at least 90% complementary, such as fully complementary, to SEQ ID NO 7 or SEQ ID NO 16.
16. The method according to any one of claims 1-15, wherein the HTRA1 mRNA antagonist is or comprises an antisense oligonucleotide, such as an LNA gapmer oligonucleotide.
17. The method according to any one of claims 1-16, wherein the HTRA1 mRNA antagonist is selected from the group consisting of: 5’T s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T 3’(SEQ ID NO 13,#13,1) 5’A s t s A s T s t s t s a s c s c s t s g s g s t s T s G s T s T 3’(SEQ ID NO 15,#15,3) 5’C s T s T s C s t s t s c s t s a s t s c s t s a s m c s g s c s A s T 3’(SEQ ID NO 17,#17), 5’T s A s C s T s t s t s a s a s t s a s g s c s T s C s A s A 3’ (SEQ ID NO 18, #18); and 5’T s T s C s t s a s t s c s t s a s m c s g s c s a s T s T s G 3’(SEQ ID NO 19,#19), The capital letters represent β-D-oxy LNA nucleoside units, the lowercase letters represent DNA nucleoside units, and the subscript s represents the phosphorothioate internucleoside linkage. m c represents 5-methylcytosine DNA nucleoside, and all LNA cytosines are 5-methylcytosine; or a pharmaceutically acceptable salt thereof.
18. A method for treating a subject having or at risk of developing macular degeneration, the method comprising performing the method according to any one of claims 1 to 17, and administering to the subject an effective amount of an HTRA1 mRNA antagonist.
19. The method of any one of claims 1-18, wherein the HTRA1 mRNA antagonist is for administration via intravitreal administration.
20. Use of HTRA1 antibodies as companion diagnostics for HTRA1 RNA antagonist therapy.
21. Use of an HTRA1 antibody as a biomarker for therapeutic efficacy of an HTRA1 RNA antagonist, such as an HTRA1 mRNA antagonist, such as an HTRA1 mRNA antagonist according to any one of the preceding claims.
22. Use of an HTRA1 antibody for detecting HTRA1 levels in an aqueous or vitreous humor sample obtained from a subject who is undergoing treatment with, or being evaluated for suitability for treatment with, an HTRA1 mRNA antagonist, such as an HTRA1 mRNA antagonist according to any one of the preceding claims.
23. Use of a biomarker for determining a subject's likely response to a therapeutic agent comprising an HTRA1 mRNA antagonist, such as according to any one of the preceding claims, wherein the biomarker comprises an elevated level of HTRA1 in a biological sample obtained from the aqueous humor or vitreous humor from the subject compared to the level of HTRA1 obtained from a reference sample of a healthy subject.
Citation Information
Patent Citations
Method and apparatus for maintaining the concentration of a liquid developing solution, in particular for a developing process using the semi-wet method
EP0002020A1
siRNA targeting HtrA serine peptidase 1
US20070185317A1
Derivatized oligonucleotides having improved uptake and other properties
WO1993007883A1
Novel bicyclonucleoside and oligonucleotide analogues
WO1998039352A1
Oligonucleotide analogues
WO1999014226A2
Cited By
Biological material for regulating and controlling HTRA1 gene expression and application of biological material in virus resistance
CN120591277A
